

Document made available under the Patent Cooperation Treaty (PCT)

International application number: PCT/US04/042173

International filing date: 15 December 2004 (15.12.2004)

Document type: Certified copy of priority document

Document details: Country/Office: US
Number: 60/531,423
Filing date: 19 December 2003 (19.12.2003)

Date of receipt at the International Bureau: 24 January 2005 (24.01.2005)

Remark: Priority document submitted or transmitted to the International Bureau in compliance with Rule 17.1(a) or (b)



World Intellectual Property Organization (WIPO) - Geneva, Switzerland
Organisation Mondiale de la Propriété Intellectuelle (OMPI) - Genève, Suisse



THE UNITED STATES OF AMERICA

TO ALL TO WHOM THESE PRESENTS SHALL COME:

UNITED STATES DEPARTMENT OF COMMERCE

United States Patent and Trademark Office

January 11, 2005

THIS IS TO CERTIFY THAT ANNEXED HERETO IS A TRUE COPY FROM THE RECORDS OF THE UNITED STATES PATENT AND TRADEMARK OFFICE OF THOSE PAPERS OF THE BELOW IDENTIFIED PATENT APPLICATION THAT MET THE REQUIREMENTS TO BE GRANTED A FILING DATE.

APPLICATION NUMBER: 60/531,423

FILING DATE: *December 19, 2003*

RELATED PCT APPLICATION NUMBER: *PCT/US04/42173*



Certified By

Jon W Dudas

Under Secretary
of Commerce for Intellectual Property
and Acting Director of the
United States Patent and Trademark Office

16569 U.S. PTO
121903

SUBSTITUTE for Provisional Application for Patent Cover Sheet PTO/SB/16 (08-03)
Approved for use through 07/31/2006. OMB 0651-0032
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

PROVISIONAL APPLICATION FOR PATENT COVER SHEET

This is a request for filing a **PROVISIONAL APPLICATION FOR PATENT** under 37 CFR 1.53 (c).

16018 U.S. PTO
60/531423
121903

DOCKET NUMBER 21592PV

INVENTOR(S)

Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
James C.	Barrow	Harleysville, PA 19438
Craig A.	Coburn	Royersford, PA 19468
Philippe G.	Nantermet	Lansdale, PA 19446
Harold G.	Selnick	Ambler, PA 19002
Shawn J.	Stachel	Perkasie, PA 18944
Matthew G.	Stanton	Conshohocken, PA 19428
Shaun R.	Stauffer	Schwenksville, PA 19473

☒ Additional inventors are being named on the 1 separately numbered sheets attached hereto

TITLE OF THE INVENTION (500 characters max)

PHENYLAMIDE AND PYRIDYLAMIDE BETA-SECRETASE INHIBITORS FOR THE TREATMENT OF ALZHEIMER'S DISEASE

CORRESPONDENCE ADDRESS

Direct all Correspondence to:

Merck & Co., Inc.
Patent Department - RY60-30
P.O. Box 2000
Rahway

☒ Customer Number 000210

STATE	New Jersey	ZIP CODE	07065	COUNTRY	U.S.A.
-------	------------	----------	-------	---------	--------

ENCLOSED APPLICATION PARTS (check all that apply)

- ☒ Specification Number of Pages 99 ☐ CD(s), Number
☐ Drawing(s) Number of Sheets
☐ Other (specify)
☐ Application Data Sheet. See 37 CFR 1.76

METHOD OF PAYMENT OF FILING FEES FOR THIS PROVISIONAL APPLICATION FOR PATENT (check one)

☐ A check or money order is enclosed to cover the filing fees

☒ The Director is hereby authorized to charge filing fees or credit any overpayment to Deposit Account Number: 13-2755

FILING FEE AMOUNT (\$) \$160.00

The invention was made by an agency of the United States Government or under a contract with an agency of the United States Government.

☒ No.

☐ Yes, the name of the U.S. Government agency and the Government contract number are: _____

Respectfully submitted,

SIGNATURE

John C. Todaro

TYPED or PRINTED NAME JOHN C. TODARO

TELEPHONE 732-5940125

Date 12/19/2003

REGISTRATION NO. 36,036
(if appropriate)

NOTE: Mail to Mail Stop Provisional Application

EXPRESS MAIL CERTIFICATE

DATE OF DEPOSIT December 19, 2003

EXPRESS MAIL NO. EL989593240US

I HEREBY CERTIFY THAT THIS CORRESPONDENCE IS BEING DEPOSITED WITH THE UNITED STATES POSTAL SERVICE AS EXPRESS MAIL "POST OFFICE TO ADDRESSEE" ON THE ABOVE DATE IN AN ENVELOPE ADDRESSED TO COMMISSIONER FOR PATENTS, P.O. BOX 1450, ALEXANDRIA, VA 22313-1450.

MAILED BY *Heidi Schepise* DATE 12-19-03

In Duplicate

PROVISIONAL APPLICATION COVER SHEET

Additional Page

DOCKET NUMBER		21592PV
INVENTOR(S)/APPLICANT(S)		
Given Name (first and middle [if any])	Family Name or Surname	Residence (City and either State or Foreign Country)
Linghang	Zhuang	Chalfont, PA 19440

NUMBER 1 of 1

TITLE OF THE INVENTION

PHENYLAMIDE AND PYRIDYLAMIDE BETA-SECRETASE INHIBITORS FOR THE
TREATMENT OF ALZHEIMER'S DISEASE

5 BACKGROUND OF THE INVENTION

Alzheimer's disease is characterized by the abnormal deposition of amyloid in the brain in the form of extra-cellular plaques and intra-cellular neurofibrillary tangles. The rate of amyloid accumulation is a combination of the rates of formation, aggregation and egress from the brain. It is generally accepted that the main constituent of amyloid plaques is the 4kD amyloid
10 protein (β A4, also referred to as $A\beta$, β -protein and β AP) which is a proteolytic product of a precursor protein of much larger size. The amyloid precursor protein (APP or $A\beta$ PP) has a receptor-like structure with a large ectodomain, a membrane spanning region and a short cytoplasmic tail. The $A\beta$ domain encompasses parts of both extra-cellular and transmembrane domains of APP, thus its release implies the existence of two distinct proteolytic events to
15 generate its NH_2 - and $COOH$ -termini. At least two secretory mechanisms exist which release APP from the membrane and generate soluble, $COOH$ -truncated forms of APP (APP_s). Proteases that release APP and its fragments from the membrane are termed "secretases." Most APP_s is released by a putative α -secretase which cleaves within the $A\beta$ protein to release α - APP_s and precludes the release of intact $A\beta$. A minor portion of APP_s is released by a β -secretase (" β -secretase"), which cleaves near the NH_2 -terminus of APP and produces $COOH$ -terminal
20 fragments (CTFs) which contain the whole $A\beta$ domain.

Thus, the activity of β -secretase or β -site amyloid precursor protein-cleaving enzyme (" $BACE$ ") leads to the abnormal cleavage of APP, production of $A\beta$, and accumulation of β amyloid plaques in the brain, which is characteristic of Alzheimer's disease (see R. N.
25 Rosenberg, *Arch. Neurol.*, vol. 59, Sep 2002, pp. 1367-1368; H. Fukumoto et al, *Arch. Neurol.*, vol. 59, Sep 2002, pp. 1381-1389; J.T. Huse et al, *J. Biol. Chem.*, vol 277, No. 18, issue of May 3, 2002, pp. 16278-16284; K.C. Chen and W.J. Howe, *Biochem. Biophys. Res. Comm*, vol. 292, pp 702-708, 2002). Therefore, therapeutic agents that can inhibit β -secretase or BACE may be useful for the treatment of Alzheimer's disease.


30 The compounds of the present invention are useful for treating Alzheimer's disease by inhibiting the activity of β -secretase or BACE, thus preventing the formation of insoluble $A\beta$ and arresting the production of $A\beta$.

SUMMARY OF THE INVENTION

The present invention is directed to phenylamide and pyridylamide derivative compounds having a terminal or branched amino or hydroxyl group. The compounds are inhibitors of the β -secretase enzyme, and are useful in the treatment of diseases in which the β -secretase enzyme is involved, such as Alzheimer's disease. The invention is also directed to pharmaceutical compositions comprising these compounds, and the use of these compounds and compositions in the treatment of such diseases in which the β -secretase enzyme is involved.

DETAILED DESCRIPTION OF THE INVENTION

The present invention is directed to compounds of formula (I):



wherein:

Y¹ is CH or N;

Q is selected from the group consisting of

- (1) -OH, and
- (2) -NH₂;

R^a is selected from the group consisting of

- (1) hydrogen,
- (2) -C₁₋₁₀ alkyl, wherein said alkyl is unsubstituted or substituted with one or more fluoro, and
- (3) -C₃₋₈ cycloalkyl;

R^b is selected from the group consisting of

- (1) hydrogen,

(2) -C₁₋₁₀ alkyl, wherein said alkyl is unsubstituted or substituted with one or more fluoro,

(3) -C₃₋₈ cycloalkyl,

5 (4) -(CH₂)_n-NR^cR^d wherein R^c and R^d are selected from the group consisting of hydrogen and C₁₋₁₀ alkyl, and n is 2, 3 or 4, and

(5) -(CH₂)_{n'}-O-R^e wherein R^e is C₁₋₁₀ alkyl, and n' is 1, 2, 3 or 4;

m is 1 or 2;

10 R¹ is (1) aryl selected from the group consisting of phenyl and naphthyl, or

(2) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,

15 (3) -C₁₋₁₀ alkyl, and

(4) -C₃₋₈ cycloalkyl,

wherein said aryl, heteroaryl, alkyl and cycloalkyl is unsubstituted or substituted with one or more

(a) halo,

20 (b) -OH,

(c) -CN,

(d) -O-C₁₋₁₀ alkyl,

(e) -C₁₋₁₀ alkyl,

(f) -C₃₋₈ cycloalkyl,

25 (g) aryl selected from the group consisting of phenyl and naphthyl, or

(h) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl,

30 benzimidazolyl and benzoxazolyl;

R² is selected from the group consisting of:

(1) (R⁴-SO₂)N(R⁷)-, wherein R⁴ is

(a) -C₁₋₁₀ alkyl,

(b) -C₃₋₈ cycloalkyl,

wherein said alkyl and cycloalkyl is unsubstituted or substituted with one or more

(i) halo,

(ii) -OH,

(iii) -CN,

(iv) -O-C₁₋₁₀ alkyl,

(v) -C₁₋₁₀ alkyl,

(vi) -C₃₋₈ cycloalkyl,

(vii) aryl selected from the group consisting of phenyl and naphthyl, or

(viii) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,

and said aryl and heteroaryl is unsubstituted or substituted with one or more

(A) halo,

(B) -OH,

(C) -CN,

(D) -O-C₁₋₁₀ alkyl,

(E) -C₃₋₈ cycloalkyl, or

(F) -C₁₋₁₀ alkyl,

(c) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,

wherein said heteroaryl is unsubstituted or substituted with one or more


(i) halo,

(ii) -OH,

- (iii) -CN,
- (iv) -O-C₁₋₁₀ alkyl,
- (v) -C₃₋₈ cycloalkyl, or
- (vi) -C₁₋₁₀ alkyl,

5

(d) $-(CH_2)_x-NR^fR^g$ wherein R^f and R^g are selected from the group consisting of hydrogen and C₁₋₁₀ alkyl, and x is 1, 2, 3 or 4 or R^f and R^g , together with the nitrogen atom to which they are attached, from the group



10

wherein y is 1 or 2, Y⁵ is -CHR²¹, -O- or NR²¹, wherein R²¹ is selected from the group consisting of;

- (i) hydrogen, and
- (ii) C₁₋₁₀ alkyl,

wherein said alkyl is unsubstituted or substituted with one or more

15

- (A) halo,
- (B) -OH,
- (C) -CN,
- (D) -O-C₁₋₁₀ alkyl, or
- (E) -C₃₋₈ cycloalkyl;

20

R⁷ is selected from the group consisting of

- (a) hydrogen, and
- (b) -C₁₋₁₀ alkyl,

wherein said alkyl is unsubstituted or substituted with one or more

25

- (i) halo,
- (ii) -OH,
- (iii) -CN,
- (iv) -O-C₁₋₁₀ alkyl,
- (v) -C₃₋₈ cycloalkyl,

30

- (vi) aryl selected from the group consisting of phenyl and naphthyl, or
- (vii) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl,

pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,

5

wherein said cycloalkyl, aryl or heteroaryl is unsubstituted or substituted with one or more

(A) halo,

(B) $-OH$,

10

(C) $-CN$,


(D) $-O-C_{1-10}$ alkyl,

(E) $-C_{3-8}$ cycloalkyl, or

(F) aryl selected from the group consisting of phenyl and naphthyl;

15

(c) $-(CH_2)_{y'}-NR^hR^i$ wherein R^h and R^i are selected from the group consisting of hydrogen and C_{1-10} alkyl, and y' is 1, 2, 3 or 4, or R^h and R^i , together with the nitrogen atom to which they are attached from the group



20

wherein y' is 1 or 2, Y^6 is $-CHR^{22}$, $-O-$ or NR^{22} , wherein R^{22} is selected from the group consisting of;

(i) hydrogen, and

(ii) C_{1-10} alkyl,

wherein said alkyl is unsubstituted or substituted with one or more

25

(A) halo,

(B) $-OH$,


(C) $-CN$,

(D) $-O-C_{1-10}$ alkyl, or

(E) $-C_{3-8}$ cycloalkyl,

30


or R^4 and R^7 are linked together to form the group



wherein z is 1, 2 or 3;

5

(2)




wherein R⁸ is selected from the group consisting of

- (a) -CN,
- (b) hydrogen, and
- (c) tetrazolyl;

10


(3)



wherein o is 1, 2, 3 or 4; and

15


(4)



wherein Y² is -NH=CH- or -CH=NH-;

20

R³ is selected from the group consisting of



wherein Y^3 is CR^{6c} or N ;

5 R^5 is C_{1-10} alkyl or C_{1-2} perfluoroalkyl;

R^{6a} , R^{6b} , and R^{6c} are independently selected from the group consisting of:

- (1) hydrogen,
- (2) halo,
- 10 (3) $-\text{C}_{1-10}$ alkyl,
- (4) $-\text{OH}$,
- (5) $-\text{CN}$,
- (6) $-\text{C}_{3-8}$ cycloalkyl, and
- (7) $-\text{O}-\text{C}_{1-10}$ alkyl;

15 R^9 and R^{10} are independently selected from the group consisting of


- (1) hydrogen,
- (2) $-\text{C}_{1-10}$ alkyl, and
- (3) $-\text{C}_{3-8}$ cycloalkyl,

20 wherein said alkyl and cycloalkyl is unsubstituted or substituted with one or more

- (a) halo,
- (b) $-\text{OH}$,
- (c) $-\text{CN}$,
- (d) $-\text{O}-\text{C}_{1-10}$ alkyl,
- 25 (e) $-\text{C}_{3-8}$ cycloalkyl, and
- (f) $-\text{NR}^j\text{R}^k$ wherein R^j and R^k are C_{1-10} alkyl;

or R^9 and R^{10} are joined together with the nitrogen atom to which they are attached to

form



5 wherein w is 1, 2 or 3, and

R²³ is selected from the group consisting of

- 10 (a) hydrogen,
 (b) -C₁₋₁₀ alkyl,
 (c) -C₃₋₈ cycloalkyl,
 (d) -C₂₋₁₀ alkenyl,
 (e) -C₂₋₁₀ alkynyl,
 (f) -(CH₂)_p-phenyl,
 15 (g) -(CH₂)_p-heteroaryl, wherein said heteroaryl is selected from the group
 consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl,
 tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl,
 triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinoliny,
 isoquinoliny, benzimidazolyl and benzoxazolyl,

20 wherein p is 0 or 1, and

wherein said alkyl, alkenyl, alkynyl, cycloalkyl, phenyl and heteroaryl is
 unsubstituted or substituted with one or more

- 25 i) halo,
 ii) -C₁₋₁₀ alkyl,
 iii) -OH,
 iv) -CN,
 v) -C₃₋₈ cycloalkyl, or
 30 vi) -O-C₁₋₁₀ alkyl;


R¹¹ is selected from the group consisting of

- (1) $-\text{CH}-$,
 (2) $-\text{CH}_2-$,
 (3) $-\text{O}-$, and
 (4) $-\text{NR}^{17}-$,

5 provided that when R^{11} is $-\text{CH}-$ the dotted line forms a bond and when R^{11} is $-\text{CH}_2-$, $-\text{O}-$ or $-\text{NR}^{17}-$ the dotted line is absent;

R^{17} is hydrogen or C_{1-10} alkyl, wherein said C_{1-10} alkyl is unsubstituted or substituted with one or more

- 10 (a) halo,
 (b) $-\text{OH}$,
 (c) $-\text{CN}$,
 (d) $-\text{C}_{3-8}$ cycloalkyl,
 (e) $-\text{O}-\text{C}_{1-10}$ alkyl,
 15 (f) $-(\text{CH}_2)_q$ -phenyl, wherein q is 1 or 2, and
 (g) $-(\text{CH}_2)_{q'}-\text{NR}^{18}\text{R}^{19}$, wherein q' is 2, 3 or 4, and
 wherein R^{18} and R^{19} are independently selected from the group consisting of
 20 i) hydrogen, or
 ii) C_{1-10} alkyl;
 or R^{18} and R^{19} , together with the nitrogen atom to which they are attached, form the group



25 wherein q'' is 1 or 2, Y^7 is $-\text{CHR}^{24}$, $-\text{O}-$ or NR^{24} , wherein R^{24} is selected from the group consisting of;

- (a) hydrogen, and
 (b) C_{1-10} alkyl,

30 wherein said alkyl is unsubstituted or substituted with one or more
 i) halo,
 ii) $-\text{OH}$,

- iii) -CN,
- iv) -O-C₁₋₁₀ alkyl, or
- v) -C₃₋₈ cycloalkyl;

- 5 R¹² is selected from the group consisting of
- (1) hydrogen,
 - (2) -C₁₋₁₀ alkyl, wherein said alkyl is unsubstituted or substituted with one or more
 - (a) halo,
 - (b) -OH,
 - 10 (c) -CN,
 - (d) -C₃₋₈ cycloalkyl,
 - (e) -O-C₁₋₁₀ alkyl, or
 - (f) -NH₂;
 - (3) halo,
 - 15 (4) -C₃₋₈ cycloalkyl,
 - (5) aryl selected from the group consisting of phenyl and naphthyl, and
 - (6) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl,
 - 20 isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,
- wherein said aryl and heteroaryl is unsubstituted or substituted with one or more
- (a) halo,
 - 25 (b) -OH,
 - (c) -CN,
 - (d) -O-C₁₋₁₀ alkyl,
 - (e) -C₃₋₈ cycloalkyl, or
 - (f) -C₁₋₁₀ alkyl;

- 30 R¹³ is selected from the group consisting of
- (1) hydrogen,
 - (2) C₁₋₁₀ alkyl, and
 - (3) -C₃₋₈ cycloalkyl;

wherein said alkyl and cycloalkyl is unsubstituted or substituted with one or more

- (a) halo,
- (b) -OH,
- (c) -CN,
- (d) -C₃₋₈ cycloalkyl,
- (e) -O-C₁₋₁₀ alkyl, and
- (f) -C₁₋₁₀ alkyl;

R¹⁴ is selected from the group consisting of

- (1) -C₁₋₁₀ alkyl, and
- (2) -C₃₋₈ cycloalkyl;

wherein said alkyl and cycloalkyl is unsubstituted or substituted with one or more

- (a) halo,
- (b) -OH,
- (c) -CN,
- (d) -C₃₋₈ cycloalkyl,
- (e) -O-C₁₋₁₀ alkyl, or
- (f) -C₁₋₁₀ alkyl;


- (3) -(CH₂)_v-NR¹⁵R¹⁶, wherein v is 2, 3 or 4, and

wherein R¹⁵ and R¹⁶ are independently selected from the group consisting of

- (a) hydrogen, or
- (b) C₁₋₁₀ alkyl, wherein said C₁₋₁₀ alkyl is unsubstituted or substituted with one or more

- (i) halo,
- (ii) -OH,
- (iii) -CN,
- (iv) -C₃₋₈ cycloalkyl, or
- (v) -O-C₁₋₁₀ alkyl;

or R¹⁵ and R¹⁶, together with the nitrogen atom to which they are attached, form the group



wherein s is 1 or 2, Y^4 is $-\text{CHR}^{24}-$, $-\text{O}-$ or $-\text{NR}^{24}-$, wherein R^{24} is selected from the group consisting of

(i) hydrogen, and

(ii) C_{1-10} alkyl,

wherein said alkyl is unsubstituted or substituted with one or more

A) halo,

B) $-\text{OH}$,

C) $-\text{CN}$,

D) $-\text{O}-\text{C}_{1-10}$ alkyl, or

E) $-\text{C}_{3-8}$ cycloalkyl,

4) $-(\text{CH}_2)_r$ -phenyl, wherein r is 1, 2, 3, or 4, and

wherein said phenyl is unsubstituted or substituted with one or more

a) halo,

b) $-\text{OH}$,


c) $-\text{CN}$,

d) $-\text{O}-\text{C}_{1-10}$ alkyl,

e) $-\text{C}_{3-8}$ cycloalkyl, or

f) $-\text{C}_{1-10}$ alkyl;

or R^{13} and R^{14} , together with the nitrogen atom to which they are attached, form the group



wherein u is 1 or 2, Y^8 is $-\text{CHR}^{25}-$, $-\text{O}-$ or $-\text{NR}^{25}-$, wherein R^{25} is selected from the group consisting of

a) hydrogen,

b) C_{1-10} alkyl,

c) $-(\text{CH}_2)_t$ -phenyl,

d) $-(CH_2)_t$ -heteroaryl, wherein said heteroaryl is selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,

wherein t is 0 or 1, and

wherein said alkyl, phenyl and heteroaryl is unsubstituted or substituted with one or more

- i) halo,
- ii) $-C_{1-10}$ alkyl,
- iii) $-OH$,
- iv) $-CN$,
- v) $-C_{3-8}$ cycloalkyl, or
- vi) $-O-C_{1-10}$ alkyl;

and pharmaceutically acceptable salts thereof.

In a preferred embodiment of the compounds of the invention, R^a and R^b are both hydrogen. In another preferred embodiment, R^a is hydrogen and R^b is as defined above. In another preferred embodiment, R^a is hydrogen and R^b is C_{1-10} alkyl, preferably C_{1-5} linear alkyl. In another preferred embodiment, Q is OH, R^a is hydrogen and R^b is $-(CH_2)_2-NR^cR^d$.

In a preferred embodiment of the compounds of the invention, R^1 is selected from the group consisting of

- (1) aryl selected from the group consisting of phenyl and naphthyl, or
 - (2) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,
- wherein said aryl or heteroaryl is unsubstituted or substituted with one or more

- (a) halo,
- (b) $-C_{1-6}$ alkyl,

- (c) -OH,
- (d) -CN, or
- (e) -O-C₁₋₆ alkyl,

wherein m is 1 or 2.

5 In a more preferred embodiment, R¹ is phenyl, unsubstituted or substituted in one or two positions with halo, preferably with fluoro or chloro, and m is 1.

In another preferred embodiment, R¹ is thienyl, unsubstituted or substituted, and m is 1.

In a more preferred embodiment, R¹ is unsubstituted 3-thienyl, and m is 1.

10 In a preferred embodiment of the compounds of the invention, R² is selected from the group consisting of

(1) (R⁴-SO₂)N(R⁷)-, wherein R⁴ is -C₁₋₆ alkyl, wherein said alkyl is unsubstituted or substituted with one or more

- (i) halo,
- (ii) -OH,
- (iii) -CN,
- (iv) -O-C₁₋₆ alkyl, or
- (v) -C₁₋₆ alkyl,


R⁷ is selected from the group consisting of

- (a) hydrogen,
- (b) -C₁₋₆ alkyl,

wherein said alkyl is unsubstituted or substituted with one or more

- (i) halo,
- (ii) -OH,
- (iii) -CN,
- (iv) -O-C₁₋₆ alkyl,
- (v) -C₁₋₆ alkyl; and

(2)



30 wherein R⁸ is phenyl or tetrazolyl, preferably 5-tetrazolyl.

In a more preferred embodiment of the compounds of the invention, R^2 is $(R^4SO_2)N(R^7)-$, wherein R^4 and R^7 are each C_{1-6} alkyl. Exemplary preferred R^2 groups include $(R^4SO_2)N(R^7)-$ wherein R^4 and R^7 are each methyl, or $(R^4SO_2)N(R^7)-$, wherein R^4 is methyl and R^7 is propyl.

5 In one embodiment of the compounds of the invention, R^3 is (1) as described above, Y^3 is CHR^{6c} , R^5 is methyl, R^{6a} and R^{6c} are hydrogen and R^{6b} is fluoro. In another preferred embodiment, R^3 is (1) as described above, Y^3 is N, R^5 is C_{1-2} perfluoroalkyl, and R^{6a} and R^{6b} are each hydrogen.

10 In another embodiment of the compounds of the invention, R^3 is (2) as described above, and R^9 and R^{10} are each unsubstituted C_{1-10} alkyl, preferably unsubstituted C_{1-5} linear alkyl. In another embodiment, R^3 is (2) as described above, and R^9 and R^{10} are joined together with the nitrogen atom to which they are attached to form a pyrrolidine ring (wherein w is 1) and R^{23} is $-(CH_2)_p$ -phenyl or $-(CH_2)_p$ -heteroaryl, wherein the phenyl and heteroaryl are unsubstituted or substituted with chloro, and wherein p is preferably 0.

15 In another embodiment, R^3 is (3) as described above, and R^{11} is NR^{17} wherein R^{17} is preferably hydrogen or C_{1-3} alkyl, and R^{12} is preferably hydrogen or methyl.


In another embodiment of the compounds of the invention, R^3 is (4) as described above, and R^{13} is hydrogen, R^{14} is $-(CH_2)_v-NR^{15}R^{16}$ wherein v is 2 and R^{15} and R^{16} are C_{1-10} alkyl, preferably C_{1-5} alkyl, which is unsubstituted or substituted with $-OH$, $-CN$ or $-OCH_3$.

20 In another embodiment, R^3 is (4) as described above, R^{13} and R^{14} are joined together with the nitrogen atom to which they are attached to form a pyrrolidine ring (when Y^8 is CH and s is 1), which is substituted with $-(CH_2)_t$ -phenyl or $-(CH_2)_t$ -heteroaryl, wherein the phenyl and heteroaryl are unsubstituted or substituted with chloro, and wherein t is preferably 0.

In another embodiment of the compounds of the invention, Y^1 is CH.

25 In another embodiment of the compounds of the invention, Y^1 is N.

One embodiment of the present invention is directed to compounds of formula (II):



wherein Q, R^a, R^b, R¹, R², R¹², R¹⁷ and m are as defined above, and pharmaceutically acceptable salts thereof.


In a preferred embodiment of the compounds of formula (II), Q is NH₂, and R^a and R^b are each hydrogen.

5 In another preferred embodiment of the compounds of formula (II), Q is NH₂, R^a is hydrogen and R^b is C₁₋₅ linear alkyl.

In a preferred embodiment of the compounds of formula (II), Q is OH, and R^a and R^b are each hydrogen.

10 In a preferred embodiment of the compounds of formula (II), Q is OH, and R^a is hydrogen and R^b is C₁₋₅ linear alkyl.

Another embodiment of the present invention is directed to compounds of the formula (III):




III

15 wherein Q, R^a, R^b, R¹, R², R¹³, R¹⁴ and m are as defined above, and pharmaceutically acceptable salts thereof.

In another embodiment of the compounds of formula (III), Q is OH and R^a and R^b are each hydrogen.

In another embodiment of the compounds of formula (III), Q is NH₂ and R^a and R^b are each hydrogen.

20 Another embodiment of the invention is directed to compounds of the formula (IV):



IV

wherein Q, R^a, R^b, R¹, R² and m are as defined above, and R³ is (1) or (2) as defined above, and pharmaceutically acceptable salts thereof. In preferred embodiments, R^a is hydrogen and R^b is C₁₋₅ linear alkyl.

Another embodiment of the present invention includes a compound which is selected
5 from the title compounds of the following Examples and pharmaceutically acceptable salts thereof.

As used herein, the term "alkyl," by itself or as part of another substituent, means a saturated straight or branched chain hydrocarbon radical having the number of carbon atoms designated (*e.g.*, C₁₋₁₀ alkyl means an alkyl group having from one to ten carbon atoms).
10 Preferred alkyl groups for use in the invention are C₁₋₆ alkyl groups, having from one to six carbon atoms. Exemplary alkyl groups include methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tert-butyl, pentyl, hexyl, and the like.

As used herein, the term "alkenyl," by itself or as part of another substituent, means a straight or branched chain hydrocarbon radical having a single carbon-carbon double bond and
15 the number of carbon atoms designated (*e.g.*, C₂₋₁₀ alkenyl means an alkenyl group having from two to ten carbon atoms). Preferred alkenyl groups for use in the invention are C₂₋₆ alkenyl groups, having from two to six carbon atoms. Exemplary alkenyl groups include ethenyl and propenyl.

As used herein, the term "alkynyl," by itself or as part of another substituent, means a straight or branched chain hydrocarbon radical having a single carbon-carbon triple bond and the
20 number of carbon atoms designated (*e.g.*, C₂₋₁₀ alkynyl means an alkynyl group having from two to ten carbon atoms). Preferred alkynyl groups for use in the invention are C₂₋₆ alkynyl groups, having from two to six carbon atoms. Exemplary alkynyl groups include ethynyl and propynyl.

As used herein, the term "cycloalkyl," by itself or as part of another substituent, means a saturated cyclic hydrocarbon radical having the number of carbon atoms designated (*e.g.*, C₃₋₈
25 cycloalkyl means a cycloalkyl group having from three to eight carbon atoms). Exemplary cycloalkyl groups include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl and the like.

The term "halo" or "halogen" includes fluoro, chloro, bromo and iodo.

30 When a heteroaryl group as defined herein is substituted, the substituent may be bonded to a ring carbon atom of the heteroaryl group, or on a heteroatom (*i.e.*, a nitrogen, oxygen or sulfur), which has a valence which permits substitution. Preferably, the substituent is bonded to a ring carbon atom.

The compounds of the instant invention have at least one asymmetric center. Additional asymmetric centers may be present depending upon the nature of the various substituents on the molecule. Compounds with asymmetric centers give rise to enantiomers (optical isomers), diastereomers (configurational isomers) or both, and it is intended that all of the possible enantiomers and diastereomers in mixtures and as pure or partially purified compounds are included within the scope of this invention. The present invention is meant to encompass all such isomeric forms of these compounds.

The independent syntheses of the enantiomerically or diastereomerically enriched compounds, or their chromatographic separations, may be achieved as known in the art by appropriate modification of the methodology disclosed herein. Their absolute stereochemistry may be determined by the x-ray crystallography of crystalline products or crystalline intermediates that are derivatized, if necessary, with a reagent containing an asymmetric center of known absolute configuration.

If desired, racemic mixtures of the compounds may be separated so that the individual enantiomers are isolated. The separation can be carried out by methods well known in the art, such as the coupling of a racemic mixture of compounds to an enantiomerically pure compound to form a diastereomeric mixture, followed by separation of the individual diastereomers by standard methods, such as fractional crystallization or chromatography. The coupling reaction is often the formation of salts using an enantiomerically pure acid or base. The diastereomeric derivatives may then be converted to the pure enantiomers by cleavage of the added chiral residue. The racemic mixture of the compounds can also be separated directly by chromatographic methods using chiral stationary phases, which methods are well known in the art.


Alternatively, any enantiomer of a compound may be obtained by stereoselective synthesis using optically pure starting materials or reagents of known configuration by methods well known in the art.

The compounds claimed in this invention can be prepared according to the following general procedures.

Scheme 1 outlines the synthesis of amino alcohols **5** and amino azides **6**. Starting from commercially available enantiopure amino esters **1**, the amine is Boc protected and the ester hydrolyzed to give acid **2**. Alternatively, commercially available enantiopure amino acids may be Boc protected using Schotten-Baumann conditions. EDC coupling of **2** with Weinreb's amine generates the Weinreb amide **3**. Treatment of the Weinreb amide with organometallic reagents gives ketones **4**. The ketones are then reduced to give a diastereomeric mixture of

- alcohols **5a**. The individual diastereomers of **5a** are either treated directly with HCl to give amino alcohol **5b** or treated with hydrazoic acid under Mitsunobu conditions to generate the desired azide. Removal of the Boc group with HCl gives the amino azide **6**. Alternatively, the Weinreb amide is reduced with lithium aluminum hydride and then treated with an
- 5 organometallic to give alcohols with opposite anti diastereoselection. Boc removal as before provides the final amines of formula type **5b**. Alternatively, commercially available epoxides can be opened with nucleophiles to give **5a**, where R^a or $R^b = CH_2Nu$.


Scheme 1



Amino alcohols of type **5b**, where R_a and $R_b = H$ (Scheme 1), may be obtained directly by reduction of the appropriate α -amino acid or α -amino methylester precursors. Intermediates **5a**, where R_a and $R_b = H$ obtained after Boc protection and reduction from an appropriate α -amino acid or α -amino methylester precursor, are carried through the Mitsunobu reaction with hydrazoic acid and deprotection as before to give amines of type **6** (R_a and $R_b = H$).


Scheme 2 describes the synthesis of amine **10** which is used in Scheme 4, second step (vide infra). In Scheme 2, propylamine is protected with benzyl chloroformate and subsequently alkylated with crotyl bromide to give **8**. Cyclopropanation followed by removal of the protecting group under hydrogenation conditions provides amine of type **10**.

Scheme 2



Scheme 3 outlines the synthesis of *trans*-methyl cyclopropylmethylamine **14**. Starting from commercially available *trans*-crotonic acid **11** the benzyl amide is generated via EDC coupling. Cyclopropanation using diazomethane and palladium acetate gives the *trans*-cyclopropane amide **13**. Reduction with borane delivers the desired amine **14**, which is used as an amine coupling partner in Scheme 4 below.


Scheme 3



Scheme 4 demonstrates a general route to acids of type **19**, **20**, **21**. The sulfonamide is coupled to methyl dichloroisonicotinate **15** using palladium catalyzed conditions. Ester **16** is then coupled to an amine (which, as an example, can include either **10** or **14**) using different palladium catalyzed conditions to give **17**. In cases where R_2 is a benzyl group, hydrogenation effectively removes the benzyl group to give **18**. Saponification of the ester gives acid **19**. Alternatively, alkylation of **18** using KHMDS and an alkyl halide introduces a second alkyl group prior to saponification to give dialkyl aminopyridine acids of type **19**.


10

Scheme 4





Scheme 5 demonstrates the preparation of acids of type **20a** from dimethyl 5-aminoisophthalate via sulfonylation followed by alkylation, hydrolysis, amide coupling and hydrolysis. Alternatively, final example compounds of type **20b** can be prepared through incorporation of the R^2 group as the final step following a sequence from dimethyl-5-bromoisophthalate involving first mono hydrolysis, followed by amide coupling, hydrolysis, a second amide coupling and a final $Pd(0)$ catalyzed cross-coupling with an appropriate amide. Acid of type **21** is prepared from dimethyl 5-iodoisophthalate via $Pd(0)$ coupling, hydrolysis, amide coupling and a final hydrolysis. Alternatively, final example compounds of the invention of type **22** and **23** can be prepared through installation of the R^2 biaryl as the final step following a sequence involving first monohydrolysis, followed by amide coupling, hydrolysis, a second amide coupling and a final Suzuki $Pd(0)$ catalyzed cross-coupling.



Scheme 5





1. R^1SO_2Cl
2. NaH, R^2I
3. aq NaOH
4. $R^9R^{10}NH$ coupling
5. aq NaOH




1. aq NaOH
2. $R^9R^{10}NH$ coupling
3. aq. NaOH
4. Amine coupling, **5b** or **6**
5. $Pd_2dba_3/XantPhos$
 $R_7NH SO_2R_4$
6. For $X = N_3$, Pd/C



1. Ar-ZnBr
 $Pd(Ph_3P)_4$
2. aq NaOH
3. $R^9R^{10}NH$ coupling
4. aq NaOH




1. aq NaOH
2. $R^9R^{10}NH$ coupling
3. aq. NaOH
4. Amine coupling, **5b** or **6**
5. $Pd(OAc)_2/TPPTS$
 $ArB(OH)_2$
6. For $X = N_3$, Pd/C






Scheme 6 illustrates the preparation of acids of type **27** and **31**. Acid of type **27** may be prepared via first alkylation of phenol **24** followed by conversion of the methyl ester to a bromomethyl functionality to give access to intermediate **25**. The cyano-cycloalkyl group is introduced via TMS-CN and the necessary dibromoalkane. Subsequent cyclopropanation followed by hydrolysis provides desired acid **27**. The preparation of acid **31** relies on similar methodology regarding the R⁷-bearing side chain and a Curtius rearrangement for the introduction of R⁷NSO₂R⁴.

Scheme 6




Scheme 7 illustrates two alternative preparations of acid of type 33. The first preparation relies on conversion of the methyl ester to an aldehyde and a Wittig coupling to install the R⁸-bearing alkene. The second preparation is based on an indenium/palladium coupling strategy.

Scheme 7



Scheme 8 depicts a final assembly of examples of type **35** and **37**. Amide coupling of acids of type 'A' (i.e. **19**, **20a**, **21**, **27**, **31**, **33**) with amines of type **5b** gives compounds of the general formula **35**. Amide coupling of acids of type 'A' (i.e. **19**, **20a**, **21**, **25**, **29**, **31**) with amines of type **6** gives the azide **33**, which after hydrogenation with palladium on carbon generates amines of the general formula **37**.

Scheme 8



The term "substantially pure" means that the isolated material is at least 90% pure, and preferably 95% pure, and even more preferably 99% pure as assayed by analytical techniques known in the art.

- 5 The term "pharmaceutically acceptable salts" refers to salts prepared from pharmaceutically acceptable non-toxic bases or acids including inorganic or organic bases and inorganic or organic acids. Salts derived from inorganic bases include aluminum, ammonium, calcium, copper, ferric, ferrous, lithium, magnesium, manganese, manganous, potassium, sodium, zinc, and the like. Particularly preferred are the ammonium, calcium, magnesium, potassium, and sodium salts. Salts in the solid form may exist in more than one crystal structure, and may also be in the form of hydrates. Salts derived from pharmaceutically acceptable organic non-toxic bases include salts of primary, secondary, and tertiary amines, substituted amines including naturally occurring substituted amines, cyclic amines, and basic ion exchange resins, such as arginine, betaine, caffeine, choline, N,N'-dibenzylethylenediamine, diethylamine, 2-diethylaminoethanol, 2-dimethylaminoethanol, ethanolamine, ethylenediamine, N-ethylmorpholine, N-ethylpiperidine, glucamine, glucosamine, histidine, hydrabamine, isopropylamine, lysine, methylglucamine, morpholine, piperazine, piperidine, polyamine resins, procaine, purines, theobromine, triethylamine, trimethylamine, tripropylamine, tromethamine, and the like.
- 15 When the compound of the present invention is basic, salts may be prepared from pharmaceutically acceptable non-toxic acids, including inorganic and organic acids. Such acids include acetic, benzenesulfonic, benzoic, camphorsulfonic, citric, ethanesulfonic, fumaric,
- 20

gluconic, glutamic, hydrobromic, hydrochloric, isethionic, lactic, maleic, malic, mandelic, methanesulfonic, mucic, nitric, pamoic, pantothenic, phosphoric, succinic, sulfuric, tartaric, p-toluenesulfonic acid, and the like. Particularly preferred are citric, hydrobromic, hydrochloric, maleic, phosphoric, sulfuric, fumaric, and tartaric acids.

5 The present invention is directed to the use of the compounds disclosed herein as inhibitors of β -secretase enzyme activity or β -site amyloid precursor protein-cleaving enzyme ("BACE") activity, in a patient or subject such as a mammal in need of such inhibition, comprising the administration of an effective amount of the compound. The terms " β -secretase enzyme," " β -site amyloid precursor protein-cleaving enzyme," and "BACE" are used
10 interchangeably in this specification. In addition to humans, a variety of other mammals can be treated according to the method of the present invention.

 The present invention is further directed to a method for the manufacture of a medicament or a composition for inhibiting β -secretase enzyme activity in humans and animals comprising combining a compound of the present invention with a pharmaceutical carrier or
15 diluent.

 The compounds of the present invention have utility in treating, ameliorating, controlling or reducing the risk of Alzheimer's disease. For example, the compounds may be useful for the prevention of dementia of the Alzheimer's type, as well as for the treatment of early stage, intermediate stage or late stage dementia of the Alzheimer's type. The compounds may also be
20 useful in treating, ameliorating, controlling or reducing the risk of diseases mediated by abnormal cleavage of amyloid precursor protein (also referred to as APP), and other conditions that may be treated or prevented by inhibition of β -secretase. Such conditions include mild cognitive impairment, Trisomy 21 (Down Syndrome), cerebral amyloid angiopathy, degenerative dementia, Hereditary Cerebral Hemorrhage with Amyloidosis of the Dutch-Type (HCHWA-D),
25 Creutzfeldt-Jakob disease, prion disorders, amyotrophic lateral sclerosis, progressive supranuclear palsy, head trauma, stroke, Down syndrome, pancreatitis, inclusion body myositis, other peripheral amyloidoses, diabetes and atherosclerosis.

 The subject or patient to whom the compounds of the present invention is administered is generally a human being, male or female, in whom inhibition of β -secretase enzyme activity is
30 desired, but may also encompass other mammals, such as dogs, cats, mice, rats, cattle, horses, sheep, rabbits, monkeys, chimpanzees or other apes or primates, for which inhibition of β -secretase enzyme activity or treatment of the above noted disorders is desired.

 The compounds of the present invention may be used in combination with one or more other drugs in the treatment of diseases or conditions for which the compounds of the present

invention have utility, where the combination of the drugs together are safer or more effective than either drug alone. Additionally, the compounds of the present invention may be used in combination with one or more other drugs that treat, prevent, control, ameliorate, or reduce the risk of side effects or toxicity of the compounds of the present invention. Such other drugs may be administered, by a route and in an amount commonly used therefor, contemporaneously or sequentially with the compounds of the present invention. Accordingly, the pharmaceutical compositions of the present invention include those that contain one or more other active ingredients, in addition to the compounds of the present invention. The combinations may be administered as part of a unit dosage form combination product, or as a kit or treatment protocol wherein one or more additional drugs are administered in separate dosage forms as part of a treatment regimen.

Examples of combinations of the compounds of the present invention with other drugs in either unit dose or kit form include combinations with: anti-Alzheimer's agents, for example other beta-secretase inhibitors or gamma-secretase inhibitors; HMG-CoA reductase inhibitors; NSAID's including ibuprofen; vitamin E; anti-amyloid antibodies; CB-1 receptor antagonists or CB-1 receptor inverse agonists; antibiotics such as doxycycline and rifampin; N-methyl-D-aspartate (NMDA) receptor antagonists, such as memantine; cholinesterase inhibitors such as galantamine, rivastigmine, donepezil, and tacrine; or other drugs that affect receptors or enzymes that either increase the efficacy, safety, convenience, or reduce unwanted side effects or toxicity of the compounds of the present invention. The foregoing list of combinations is illustrative only and not intended to be limiting in any way.

The term "composition" as used herein is intended to encompass a product comprising specified ingredients in predetermined amounts or proportions, as well as any product which results, directly or indirectly, from combination of the specified ingredients in the specified amounts. This term in relation to pharmaceutical compositions is intended to encompass a product comprising one or more active ingredients, and an optional carrier comprising inert ingredients, as well as any product which results, directly or indirectly, from combination, complexation or aggregation of any two or more of the ingredients, or from dissociation of one or more of the ingredients, or from other types of reactions or interactions of one or more of the ingredients. In general, pharmaceutical compositions are prepared by uniformly and intimately bringing the active ingredient into association with a liquid carrier or a finely divided solid carrier or both, and then, if necessary, shaping the product into the desired formulation. In the pharmaceutical composition the active object compound is included in an amount sufficient to produce the desired effect upon the process or condition of diseases. Accordingly, the

pharmaceutical compositions of the present invention encompass any composition made by admixing a compound of the present invention and a pharmaceutically acceptable carrier.

Pharmaceutical compositions intended for oral use may be prepared according to any method known to the art for the manufacture of pharmaceutical compositions and such
5 compositions may contain one or more agents selected from the group consisting of sweetening agents, flavoring agents, coloring agents and preserving agents in order to provide pharmaceutically elegant and palatable preparations. Tablets may contain the active ingredient in admixture with non-toxic pharmaceutically acceptable excipients which are suitable for the manufacture of tablets. These excipients may be, for example, inert diluents, such as calcium
10 carbonate, sodium carbonate, lactose, calcium phosphate or sodium phosphate; granulating and disintegrating agents, for example, corn starch, or alginic acid; binding agents, for example starch, gelatin or acacia, and lubricating agents, for example magnesium stearate, stearic acid or talc. The tablets may be uncoated or they may be coated by known techniques to delay disintegration and absorption in the gastrointestinal tract and thereby provide a sustained action
15 over a longer period.

Compositions for oral use may also be presented as hard gelatin capsules wherein the active ingredient is mixed with an inert solid diluent, for example, calcium carbonate, calcium phosphate or kaolin, or as soft gelatin capsules wherein the active ingredient is mixed with water or an oil medium, for example peanut oil, liquid paraffin, or olive oil.

20 Other pharmaceutical compositions include aqueous suspensions, which contain the active materials in admixture with excipients suitable for the manufacture of aqueous suspensions. In addition, oily suspensions may be formulated by suspending the active ingredient in a vegetable oil, for example arachis oil, olive oil, sesame oil or coconut oil, or in a mineral oil such as liquid paraffin. Oily suspensions may also contain various excipients. The
25 pharmaceutical compositions of the invention may also be in the form of oil-in-water emulsions, which may also contain excipients such as sweetening and flavoring agents.

The pharmaceutical compositions may be in the form of a sterile injectable aqueous or oleaginous suspension, which may be formulated according to the known art, or may be administered in the form of suppositories for rectal administration of the drug.

30 The compounds of the present invention may also be administered by inhalation, by way of inhalation devices known to those skilled in the art, or by a transdermal patch.

By "pharmaceutically acceptable" it is meant the carrier, diluent or excipient must be compatible with the other ingredients of the formulation and not deleterious to the recipient thereof.

The terms "administration of" or "administering a" compound should be understood to mean providing a compound of the invention to the individual in need of treatment in a form that can be introduced into that individual's body in a therapeutically useful form and therapeutically useful amount, including, but not limited to: oral dosage forms, such as tablets, capsules, syrups, suspensions, and the like; injectable dosage forms, such as IV, IM, or IP, and the like; transdermal dosage forms, including creams, jellies, powders, or patches; buccal dosage forms; inhalation powders, sprays, suspensions, and the like; and rectal suppositories.

The terms "effective amount" or "therapeutically effective amount" means the amount of the subject compound that will elicit the biological or medical response of a tissue, system, animal or human that is being sought by the researcher, veterinarian, medical doctor or other clinician. As used herein, the term "treatment" refers to the treatment of the mentioned conditions, particularly in a patient who demonstrates symptoms of the disease or disorder.

As used herein, the term "treatment" or "treating" means any administration of a compound of the present invention and includes (1) inhibiting the disease in an animal that is experiencing or displaying the pathology or symptomatology of the diseased (i.e., arresting further development of the pathology and/or symptomatology), or (2) ameliorating the disease in an animal that is experiencing or displaying the pathology or symptomatology of the diseased (i.e., reversing the pathology and/or symptomatology). The term "controlling" includes preventing treating, eradicating, ameliorating or otherwise reducing the severity of the condition being controlled.

The compositions containing compounds of the present invention may conveniently be presented in unit dosage form and may be prepared by any of the methods well known in the art of pharmacy. The term "unit dosage form" is taken to mean a single dose wherein all active and inactive ingredients are combined in a suitable system, such that the patient or person administering the drug to the patient can open a single container or package with the entire dose contained therein, and does not have to mix any components together from two or more containers or packages. Typical examples of unit dosage forms are tablets or capsules for oral administration, single dose vials for injection, or suppositories for rectal administration. This list of unit dosage forms is not intended to be limiting in any way, but merely to represent typical examples of unit dosage forms.

The compositions containing compounds of the present invention may conveniently be presented as a kit, whereby two or more components, which may be active or inactive ingredients, carriers, diluents, and the like, are provided with instructions for preparation of the actual dosage form by the patient or person administering the drug to the patient. Such kits may

be provided with all necessary materials and ingredients contained therein, or they may contain instructions for using or making materials or components that must be obtained independently by the patient or person administering the drug to the patient.

When treating, ameliorating, controlling or reducing the risk of Alzheimer's disease or other diseases for which compounds of the present invention are indicated, generally satisfactory results are obtained when the compounds of the present invention are administered at a daily dosage of from about 0.1 milligram to about 100 milligram per kilogram of animal body weight, preferably given as a single daily dose or in divided doses two to six times a day, or in sustained release form. The total daily dosage is from about 1.0 milligrams to about 2000 milligrams, preferably from about 0.1 milligrams to about 20 milligrams per kilogram of body weight. In the case of a 70 kg adult human, the total daily dose will generally be from about 7 milligrams to about 1,400 milligrams. This dosage regimen may be adjusted to provide the optimal therapeutic response. The compounds may be administered on a regimen of 1 to 4 times per day, preferably once or twice per day.

Specific dosages of the compounds of the present invention, or pharmaceutically acceptable salts thereof, for administration include 1 mg, 5 mg, 10 mg, 30 mg, 80 mg, 100 mg, 150 mg, 300 mg and 500 mg. Pharmaceutical compositions of the present invention may be provided in a formulation comprising about 0.5 mg to 1000 mg active ingredient; more preferably comprising about 0.5 mg to 500 mg active ingredient; or 0.5 mg to 250 mg active ingredient; or 1 mg to 100 mg active ingredient. Specific pharmaceutical compositions useful for treatment may comprise about 1 mg, 5 mg, 10 mg, 30 mg, 80 mg, 100 mg, 150 mg, 300 mg and 500 mg of active ingredient.

It will be understood, however, that the specific dose level and frequency of dosage for any particular patient may be varied and will depend upon a variety of factors including the activity of the specific compound employed, the metabolic stability and length of action of that compound, the age, body weight, general health, sex, diet, mode and time of administration, rate of excretion, drug combination, the severity of the particular condition, and the host undergoing therapy.

The utility of the compounds in accordance with the present invention as inhibitors of β -secretase enzyme activity may be demonstrated by methodology known in the art. Enzyme inhibition is determined as follows.

FRET Assay: A homogeneous end point fluorescence resonance energy transfer (FRET) assay is employed with the substrate ([TAMRA-5-CO-EEISEVNLD AEF-NHQS Y] QFRET), which is cleaved by BACE 1 to release the fluorescence from TAMRA. The K_m of the substrate

is not determined due to the limit of solubility of the substrate. A typical reaction contains approximately 30 nM enzyme, 1.25 μ M of the substrate, and buffer (50 mM NaOAc, pH 4.5, 0.1 mg/ml BSA, 0.2% CHAPS, 15 mM EDTA and 1 mM deferoxamine) in a total reaction volume of 100 μ l. The reaction is proceeded for 30 min and the liberation of TAMRA fragment is measured in a 96-well plate LYL Analyst AD using an excitation wavelength of 530 nm and an emission wavelength of 580 nm. Under these conditions, less than 10% of substrate is processed by BACE 1. The enzyme used in these studies was soluble (transmembrane domain and cytoplasmic extension excluded) human protein produced in a baculovirus expression system. To measure the inhibitory potency of compounds, solutions of inhibitor in DMSO (four concentrations of the inhibitors were prepared: 1mM, 100 μ M, 10 μ M, 1 μ M) were included in the reactions mixture (final DMSO concentration is 0.8%). All experiments were conducted at room temperature using the standard reaction conditions described above. To determine the IC₅₀ of the compound, competitive equation $V_0/V_i = 1 + [I]/IC_{50}$ were employed to predict the inhibitory potency of the compounds. The errors in reproducing the dissociation constants are typically less than two-fold.

HPLC assay: A homogeneous end point HPLC assay is employed with the substrate (coumarin-CO-REVNFEVEFR), which is cleaved by BACE 1 to release the N-terminal fragment attached with coumarin. The K_m of the substrate is greater than 100 μ M and can not be determined due to the limit of solubility of the substrate. A typical reaction contains approximately 2 nM enzyme, 1.0 μ M of the substrate, and buffer (50 mM NaOAc, pH 4.5, 0.1 mg/ml BSA, 0.2% CHAPS, 15 mM EDTA and 1 mM deferoxamine) in a total reaction volume of 100 μ l. The reaction is proceeded for 30 min and the reaction is stopped by the addition of 25 μ L of 1 M Tris-HCl, pH 8.0. The resulting reaction mixture was loaded on the HPLC and the product was separated from substrate with 5 min linear gradient. Under these conditions, less than 10% of substrate is processed by BACE 1. The enzyme used in these studies was soluble (transmembrane domain and cytoplasmic extension excluded) human protein produced in a baculovirus expression system. To measure the inhibitory potency for compounds, solutions of inhibitor in DMSO (12 concentrations of the inhibitors were prepared and the concentration range was dependent on the potency predicted by FRET) were included in the reaction mixture (final DMSO concentration is 10 %). All experiments were conducted at room temperature using the standard reaction conditions described above. To determine the IC₅₀ of the compound, four parameters equation is employed for curve fitting. The errors in reproducing the dissociation constants are typically less than two-fold.

In particular, the compounds of the following examples had activity in inhibiting the beta-secretase enzyme in the aforementioned assay, generally with an IC₅₀ from about 1 nM to 100 μM. Such a result is indicative of the intrinsic activity of the compounds in use as inhibitors the beta-secretase enzyme activity.

Several methods for preparing the compounds of this invention are illustrated in the Schemes and Examples herein. Starting materials are made according to procedures known in the art or as illustrated herein. The following examples are provided so that the invention might be more fully understood. These examples are illustrative only and should not be construed as limiting the invention in any way.

The following abbreviations are used throughout the text:

Ar: aryl

Ph: phenyl

Me: methyl

Et: ethyl

Bu: butyl

Ac: acetyl

Bn: benzyl

DMF: N,N'-dimethyl formamide

THF: tetrahydrofuran

DMSO: dimethylsulfoxide

HPLC: high performance liquid chromatography

EDTA: ethylene diamine tetraacetic acid

Boc: tert-butyloxy carbonyl

Cbz: Benzyloxycarbonyl

DIBAL: diisobutylaluminium hydride

BOP: Benzotriazol-1-yloxy-tris(dimethylamino)phosphonium hexafluorophosphate

TMS: trimethylsilyl

BSA: bovine serum albumin

CHAPS: 3-[(3-cholamidopropyl)dimethylammonio]-2-hydroxy-1-propanesulfonate

TEA: triethylamine

EDC: 1-ethyl-3-(3-dimethylaminopropyl)-carbodiimide

LAH: lithium aluminum hydride

TPPTS: triphenylphosphine trisulfonate

NIS: N-iodo succinimide

DEAD: diethylazole dicarboxylate

TPP: triphenyl phosphate

KHMDS: potassium bis(trimethylsilyl)amide

5 dba: di-n-butylamine

DIPEA: diisopropylethylamine


RT: room temperature

DCM: dichloromethane

TfOH: trifluoromethane sulfonic acid

10 HOAT: 1-hydroxy-7-azabenzotriazole

Nu: nucleophile

Intermediate I: (2S,3S)-3-azido-1-phenylheptan-2-amine (Scheme 1)

Step A: Ketone preparation

To a solution of N-Boc-phenylalanine-Weinreb amide (2.19 g, 7.10 mmol) in 50 mL Et₂O cooled to -78 °C was added nBuLi (15.5 mL, 24.86 mmol, 1.6 M in hexane) dropwise, via syringe. After stirring at -78 °C for 3 h, an additional 10 mL nBuLi was added and the reaction mixture was stirred at -78 °C for 1 h. The reaction mixture was quenched with water, allowed to warm to room temperature, diluted with water, Et₂O and EtOAc, the organic layer was extracted, washed with 10% KHSO₄, aq NaHCO₃, and brine, dried over sodium sulfate, and concentrated in vacuo to afford crude tert-butyl (1S)-1-benzyl-2-oxohexylcarbamate as a pale yellow oil which was used as is in the following reduction step.

Step B: Reduction

To a solution of tert-butyl (1S)-1-benzyl-2-oxohexylcarbamate (1.81 g, 5.93 mmol) in 65 mL ethanol cooled to -78 °C was added NaBH₄ (269 mg, 7.11 mmol). The reaction mixture was stirred at -78 °C for 24 h and allowed to slowly warm to room temperature. The reaction mixture was quenched with 2.5 mL water and concentrated in vacuo. The reaction mixture was partitioned between water and EtOAc, the organic layer was washed with brine, dried over sodium sulfate, and concentrated in vacuo, combined with a previous 440 mg tert-butyl (1S)-1-benzyl-2-oxohexylcarbamate probe reaction, and purified by flash chromatography (300 g silica, 0 -> 30% EtOAc/hexanes, then repeat on mix: 165 g silica, 10 -> 40% EtOAc/hexanes) to afford the anti diastereoisomer and the desired syn isomer tert-butyl (1S,2R)-1-benzyl-2-hydroxyhexylcarbamate as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.32-7.06 (m, 5H), 4.68-4.48 (m, 1H), 3.88-3.75 (m, 1H), 3.75-3.64 (m, 1H), 2.89 (A of ABX, dd, J = 14.0, 4.4 Hz, 1H), 2.80-2.75 (m, B of ABX, 1H), 2.50 (br s, 1H), 1.60-1.20 (m, 6H), 1.35 (s, 9H), 0.52 (t, J = 7.0 Hz, 3H).

Step C: Azide introduction


To a solution of tert-butyl (1S,2R)-1-benzyl-2-hydroxyhexylcarbamate (1.24 g, 4.03 mmol), triphenylphosphine (1.06 g, 4.03 mmol) in 40 mL THF was added hydrazoic acid HN₃ (4 mL, 8.07 mmol, 2M in benzene) followed by dropwise addition of diethylazodicarboxylate (0.7 mL,

4.44 mmol) in 10 mL THF. The reaction mixture was stirred at room temperature for 8 h, combined with a previous 250 mg tert-butyl (1S,2R)-1-benzyl-2-hydroxyhexylcarbamate probe reaction, concentrated in vacuo, and purified by flash chromatography (120 g silica, 0 → 50% EtOAc/hexanes) to afford tert-butyl (1S,2R)-1-benzyl-2-hydroxyhexylcarbamate and tert-butyl (1S,2S)-2-azido-1-benzylhexylcarbamate as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.36-7.16 (m, 5H), 4.63 (d, J = 10.1 Hz, 1H), 4.00-3.88 (m, 1H), 3.40-3.28 (m, 1H), 2.91 (A of ABX, dd, J = 13.6, 6.8 Hz, 1H), 2.76 (B of ABX, dd, J = 13.6, 9.1 Hz, 1H), 1.70-1.48 (m, 2H), 1.42-1.20 (m, 4H), 1.39 (s, 9H), 0.52 (t, J = 7.1 Hz, 3H).

10 Step D: Boc removal


Through a solution of tert-butyl (1S,2S)-2-azido-1-benzylhexylcarbamate (478 mg, 1.44 mmol) in 50 mL EtOAc cooled to 0 °C was bubbled HCl(g) for 5 min. The reaction mixture was allowed to warm to room temperature, concentrated in vacuo to afford (2S,3S)-3-azido-1-phenylheptan-2-amine hydrochloride **I** as a white solid. ¹H NMR (400 MHz, CD₃OD) δ 7.42-7.35 (m, 2H), 7.26-7.35 (m, 3H), 3.60-3.51 (m, 2H), 3.08-2.95 (m, 2H), 1.80-1.61 (m, 2H), 1.45-1.26 (m, 4H), 0.92 (t, J = 7.7 Hz, 3H).

Intermediate II: (2S,3R)-3-azido-1-phenylheptan-2-amine (Scheme 1)



- 20 Prepared from the anti diastereoisomer tert-butyl (1S,2S)-1-benzyl-2-hydroxyhexylcarbamate (intermediate I, step B) using a similar procedure as described in intermediate I steps C and D. ES MS (M+H) = 233.


Intermediate III: (2S,3S)-3-hydroxy-1-phenylheptan-2-amine (Scheme 1)



25


Prepared from the Boc removal of the anti diastereoisomer tert-butyl (1S,2S)-1-benzyl-2-hydroxyhexylcarbamate (intermediate I, step B) using a similar procedure as described in intermediate I step D. ES MS (M+H) = 208.

5 Intermediate IV: (2S,3R)-3-hydroxy-1-phenylheptan-2-amine (Scheme 1)




Prepared from the Boc removal of the syn diastereoisomer tert-butyl (1S,2R)-1-benzyl-2-hydroxyhexylcarbamate (intermediate I, step B) using a similar procedure as described in intermediate I step D. ES MS (M+H) = 208.

10 Intermediate V: (2R,3S)-3-azido-1-thien-3-ylheptan-2-amine (Scheme 1)




Prepared from Boc aminoacid in manner similar to that used to prepare Intermediate I: ES MS (M+H) = 239.

15 Intermediate VI: (2R,3S)-3-azido-1-thien-3-ylbutan-2-amine (Scheme 1)



Prepared from Boc aminoacid in a manner similar to that used to prepare Intermediate I: ES MS (M+H) = 197.

20 Intermediate VII: (2R,3S)-2-amino-1-thien-3-ylheptan-3-ol (Scheme 1)




Prepared from the Boc removal of the anti diastereoisomer tert-butyl (1R,2S)-2-hydroxy-1-(thien-3-ylmethyl)hexylcarbamate using a similar procedure as described in intermediate I step

D. ES MS (M+H) = 214.

5


Intermediate VIII: (1R,2S)-2-azido-1-(3,5-difluorobenzyl)hexylamine (Scheme 1)



Prepared from Boc aminoacid in manner similar to that used to prepare Intermediate I: ES MS (M+H) = 269.

10

Intermediate IX: (2R,3S)-2-amino-1-(3,5-difluorophenyl)heptan-3-ol (Scheme 1)



Prepared from the Boc removal of the anti diastereoisomer tert-butyl (1R,2S)-1-(3,5-difluorobenzyl)-2-hydroxyhexylcarbamate using a similar procedure as described in intermediate

I step D. ES MS (M+H) = 244.

15

Intermediate X: N-[(2-methylcyclopropyl)methyl]propan-1-amine (Scheme 2)



Step A: Cbz protection

A solution of propylamine (9.0g, 152.4 mmol) and triethylamine (15.4g, 152.4 mmol) in methylene chloride (350 mL) was cooled to 0 °C and treated with benzyl chloroformate (20.0g, 117.2 mmol). Upon stirring at 0 °C for 1 hour the reaction was warmed to ambient temperature and quenched with 1N HCl. The reaction was partitioned between 1N HCl and methylene chloride. The organics were washed with 1N HCl, water and brine. The combined organics were dried over sodium sulfate, filtered and evaporated *in vacuo* to give benzyl propylcarbamate as a clear oil. ¹H NMR (400 MHz, CDCl₃) δ 7.37 (m, 5H), 5.10 (s, 2H), 4.77 (bs, 1H), 3.16 (q, J = 6.5 Hz, 2H), 1.52 (m, 2H), 0.92 (t, J = 7.5 Hz, 3H).

Step B: Alkylation

A solution of benzyl propylcarbamate (20.8g, 107.9 mmol) in DMF (200 mL) was cooled to 0 °C and treated with sodium hydride (4.6g, 194.2 mmol). The reaction was stirred to 0 °C for 15 minutes and subsequently treated with crotyl bromide (17.5g, 129.5 mmol). The reaction was warmed to ambient temperature and stirred for 16 hours. The reaction was quenched with ammonium chloride solution and partitioned between water and ether. The organics were washed with water (4x) and brine, dried over sodium sulfate, filtered and evaporated *in vacuo*. Flash chromatography (silica, 0-10% EtOAc/hexanes) gave benzyl (2E)-but-2-enyl(propyl)carbamate as a clear oil. ¹H NMR (400 MHz, CDCl₃) δ 7.35 (m, 5H), 5.57 (bt, 1H), 5.42 (bs, 1H), 5.13 (s, 2H), 3.82 (bm, 2H), 3.19 (bs, 2H), 1.68 (bs, 3H), 1.54 (bs, 2H), 0.87 (bs, 3H).


Step C: Cyclopropanation

A solution of benzyl (2E)-but-2-enyl(propyl)carbamate (5.0g, 20.2 mmol) in methylene chloride (120 mL) was cooled to 0 °C and treated with diethylzinc (12.48g, 101 mmol) followed by diiodomethane (54.1g, 202 mmol). The reaction was warmed to ambient temperature and stirred for 16 hours. The reaction was quenched with saturated ammonium chloride solution and partitioned between methylene chloride and saturated sodium bicarbonate solution. The organics were dried over sodium sulfate, filtered and evaporated *in vacuo*. Flash chromatography (10% EtOAc/hexanes) gave 5.16g (96%) of benzyl (2-methylcyclopropyl)methyl(propyl)carbamate as a yellow oil. ¹H NMR (400 MHz, CDCl₃) δ 7.35 (m, 5H), 5.13 (s, 2H), 3.16 (bm, 4H), 1.59 (bm, 2H), 1.01 (bs, 3H), 0.88 (bs, 3H), 0.68 (bs, 2H), 0.34 (bd, 1H), 0.22 (bs, 2H).

Step D: Hydrogenation

A solution of benzyl (2-methylcyclopropyl)methyl(propyl)carbamate (5.5g, 21.0 mmol), 10% palladium on carbon (0.25g) and 12M HCl (3.0 mL) in degassed methanol (100 mL) was placed under a hydrogen atmosphere for 16 hours. The reaction was degassed with nitrogen, filtered through celite, rinsed with methanol and evaporated *in vacuo* to give 2.61g (97%) of N-[(2-methylcyclopropyl)methyl propan-1-amine hydrochloride. The salt was partitioned between 1M NaOH and ether. The organics were dried over sodium sulfate, filtered and evaporated *in vacuo* to give N-[(2-methylcyclopropyl)methyl propan-1-amine. ¹H NMR (400 MHz, CD₃OD) δ 2.50 (m, 4H), 1.54 (m, 2H), 1.05 (m, 3H), 0.93 (m, 3H), 0.62 (m, 2H), 0.33 (m, 1H), 0.24 (m, 1H).

Intermediate XI: N-benzyl-1-(2-*trans*-methylcyclopropyl)methanamine (Scheme 3)



Step A: Coupling

In a 2L flask *trans*-crotonic acid (15.0 g, 174 mmol), benzyl amine (20.5 g, 192 mmol) and DIPEA (36.7 g, 192 mmol) were dissolved in 700 mL of dichloromethane. To this solution at room temperature EDC-HCl (36.7 g, 192 mmol) was added as a solid portionwise and stirred overnight. The reaction mixture was poured onto 10% aq. KHSO₄ (250mL). The layers were separated and washed once again with 10% aq. KHSO₄. The organic layer was subsequently washed with H₂O (200mL) followed by brine (150mL), dried over Na₂SO₄ and concentrated to dryness to white crystals of (*2E*)-*N*-benzylbut-2-enamide: ¹H NMR (400 MHz, CDCl₃) δ 7.28 (m, 5H), 6.85 (sext, J = 6.8 Hz, 1H), 5.78 (dd, J = 15.2, 1.6 Hz, 2H), 4.47 (d, J = 5.6 Hz, 2H), 1.82 (dd, J = 7.2, 1.6 Hz, 3H).

Step B: Cyclopropanation

In an Erlenmeyer flask containing Et₂O (300 mL) and aq. 40% KOH (111mL) with vigorous stirring was added 1-methyl-3-nitro-1-nitrosoguanidine (11.1 g, 67 mmol) portionwise over 5 min. at room temperature. Upon complete addition stirring was ceased and the aq. layer frozen in a -78deg bath. The ether layer was decanted into an Erlenmeyer with KOH pellets. The contents allowed to stand for 5 min., decanted into a third flask with KOH pellets and then poured onto a Et₂O/THF solution (200 mL/50 mL) containing (*2E*)-*N*-benzylbut-2-enamide (3.0 g, 17.1 mmol from step A). Pd(OAc)₂ (180 mg, 0.9 mmol) was subsequently added and the reaction allowed to warm to rt and stir for 1h. Nitrogen was bubbled through the reaction for 10min. The mixture was washed with H₂O (150 mL). The organic layer was isolated and

subsequently dried over Na₂SO₄. Solvent removal and purification by flash chromatography on SiO₂ (EtOAc/hexanes) gave N-benzyl-*trans*-2-methylcyclopropanecarboxamide (83%): ¹H NMR (400 MHz, CDCl₃) δ 7.28 (m, 5H), 5.81 (br s, 1H), 4.43 (dd, J = 5.6, 2.4 Hz, 2H), 1.37 (m, 1H), 1.17 (m, 1H), 1.07 (d, J = 6.0 Hz, 3H), 1.04 (overlapping m, 1H), 0.56 (m, 1H).


5

Step C: Reduction

A 500mL flask charged with N-benzyl-*trans*-2-methylcyclopropanecarboxamide (from step B, 3.9 g, 20.6 mmol) in THF (80mL) was added BH₃-THF (1.0 M, 105mL, 105 mmol) dropwise via an addition funnel. Upon complete addition (10 min.) the mixture was refluxed for 5h. The mixture was allowed to cool to room temperature and quenched carefully with MeOH (15mL). The mixture was concentrated to dryness, dissolved in dichloromethane and washed with 3M KOH. The organic layer was isolated, washed with brine, then dried over Na₂SO₄ and concentrated to dryness. The crude material was treated with 1N HCl in dioxane for 1h at 50 °C. The mixture was concentrated to give hydrochloride salt as a white solid. The solid was dissolved in sat. aq. NaHCO₃ (80 mL) and extracted with CHCl₃ (2x150 mL). The combined organic layers were washed with brine, dried over Na₂SO₄ and the solvent removed via rotary evaporation to give after drying in vacuo N-benzyl-1-(2-*trans*-methylcyclopropyl)methanamine as an off-white semi-solid (quant.): ¹H NMR (400 MHz, CDCl₃) δ 7.28 (m, 5H), 3.80 (s, 2H), 2.50 (d, J = 6.8 Hz, 2H), 2.4 (br s, 1H), 1.02 (d, J = 6.0 Hz, 3H), 0.69 (m, 1H), 0.52 (m, 1H), 0.23 (m, 2H).

20

Intermediate XII: N-(2S,3RS)-2-amino-5-(dimethylamino)-1-phenylpentan-3-ol (Scheme 1)



Prepared according to Scheme 1 in an analogous manner as intermediate III with the one additional step; step B involving Michael addition using dimethyl amine (vida infra).

25

Step A: To a solution of N-Boc-phenylalanine-Weinreb amide (10.0 g, 32.4 mmol) in 200 mL THF cooled to -40 °C was added vinyl magnesium bromide (97.0 mL, 97.0 mmol, 1.0 M in THF) dropwise. After stirring at -40 to -20°C for 5 h. The reaction mixture was poured onto cold 3N HCl (600mL), extracted with EtOAc (3x200mL), the organic layers combined and washed with brine, dried over sodium sulfate, and concentrated in vacuo to afford crude tert-


30

butyl (1S)-1-benzyl-2-oxobut-3-enylcarbamate which was used as is in the following Michael addition reaction.

- Step B: In a flask containing tert-butyl (1S)-1-benzyl-2-oxobut-3-enylcarbamate (0.75 g, 2.72 mmol) in MeOH (10mL) was added dimethyl amine (2.73 mL, 2.0 M MeOH, 5.45 mmol). The mixture was stirred at rt for 1h. The mixture was concentrated to dryness to give tert-butyl (1S)-1-benzyl-4-(dimethylamino)-2-oxobutylcarbamate which was used in the next reaction without further purification.
- Step C: In a 50mL flask containing ketone (825mg, 2.57 mmol) from step B in 25mL of EtOH at room temperature was added NaBH₄ (92mg, 2.57 mmol) in two portions. The mixture was stirred overnight and 1mL of H₂O added. The reaction was concentrated to dryness and partitioned between EtOAc and H₂O. The layers were separated and the aqueous layer extracted once again. The combined organic layers were washed with brine, dried over Na₂SO₄ and concentrated to dryness to give crude tert-butyl (1S,2RS)-1-benzyl-4-(dimethylamino)-2-hydroxybutylcarbamate. ¹H NMR indicated a mixture of alpha and beta diastereomers. The crude material was deprotected in step D below without further purification.


- Step D: A scintillation vial containing tert-butyl (1S,2RS)-1-benzyl-4-(dimethylamino)-2-hydroxybutylcarbamate (250mg, 0.78 mmol) in EtOAc was cooled to 0 °C. HCl (g) was gently bubbled into the mixture for ca. 1min. The vial was sealed with a cap and allowed to warm to rt. After 30min. the mixture was concentrated with N₂ and then concentrated further via rotary evaporation to give an off-white solid intermediate XII, *N*-(2S,3RS)-2-amino-5-(dimethylamino)-1-phenylpentan-3-ol as hydrochloride salt: (2 : 1 ratio of diastereomers, major isomer reported) ¹H NMR (400 MHz, MeOD) δ 7.28 (m, 5H), 3.91 (dt, J= 6.9 Hz, 3.6 Hz, 1H), 3.61 (m, 1H), 3.35 (m, 2H) 3.22 (m, 2H), 2.9-3.0 (overlapping m, 2H), 2.89 (s, 6H); ES MS (M+H) = 223.3.

Intermediate XIII: (2S,3R)-3-azido-1-phenylbutan-2-amine (Scheme 1)



Prepared from Boc aminoacid in manner similar to that used to prepare Intermediate I: ES MS (M+H) = 191.

Intermediate XIV: (2S,3R)-3-azido-4-fluoro-1-phenylbutan-2-amine (Scheme 1)



5

Step A: Epoxide opening


tert-Butyl[(1S)-1-oxiran-2-yl-2-phenylethyl]carbamate (1.0g, 3.8 mmol), potassium fluoride hydrogen fluoride (0.59g, 7.6 mmol) and *N,N,N*-tributylbutan-1-aminium fluoride dihydrofluoride (0.06g, 0.19 mmol) in chlorobenzene (2.0 mL) was heated to 120 °C for 16 hours. The reaction was cooled to ambient temperature, diluted with methylene chloride, filtered through celite and evaporated *in vacuo*. Flash column chromatography (silica, 25% ethyl acetate/hexanes) generated 0.29g (27%) of desired alcohol as a white solid. ¹H NMR (400 MHz, CDCl₃) δ 7.28 (m, 5H), 4.61 (bs, 1H), 4.54 (m, 1H), 4.43 (m, 1H) 3.93 (bm, 2H), 3.24 (bs, 1H), 2.93 (bm, 2H), 1.38 (s, 9H); ES MS (M+H-tBu) = 228.3.

15

Prepared by analogous steps C and D in intermediate I: ES MS (M + H) = 209.3.

20

Intermediate A: 2-[(2-methylcyclopropyl)methyl]amino}-6-[methyl(methylsulfonyl)amino]isonicotinic acid (Scheme 4)



Step A: Sulfonamide incorporation

Methyl 2,6-dichloroisonicotinate (5.0g, 24.3 mmol), methyl(methylsulfonyl)amine (3.18g, 29.12 mmol), potassium phosphate (7.22g, 34.0 mmol), Xantphos (0.87g, 1.50 mmol) and tris(dibenzylideneacetone)dipalladium (0.68g, 0.51 mmol) were added to a dry, argon flushed flask. Dioxane (195 mL) was added, the solution degassed with argon and the reaction was heated to 100 °C for 16 hours. The reaction was cooled to rt, filtered through celite and evaporated *in vacuo*. Flash chromatography (silica, 0-50% EtOAc/CH₂Cl₂) gave methyl 2-chloro-6-[methyl(methylsulfonyl)amino]isonicotinate as a yellow oil: ¹H NMR (400 MHz, CDCl₃) δ 7.88 (s, 1H), 7.68 (s, 1H), 3.96 (s, 3H), 3.44 (s, 3H), 3.11 (s, 3H).

10 Step B: Amination

A solution of methyl 2-chloro-6-[methyl(methylsulfonyl)amino]isonicotinate (1.2g, 4.30 mmol), amine **XI** (1.0g, 5.60 mmol), potassium phosphate (2.74g, 12.9 mmol), and palladium bis(tri-*t*-butylphosphine) (0.11g, 0.22 mmol) in degassed toluene (15 mL) was sealed in a glass tube and heated to 110 °C for 16 hours. The reaction was filtered through celite, rinsed with ethyl acetate and concentrated *in vacuo*. Flash chromatography (silica, 20% EtOAc/hexanes) gave methyl 2-{benzyl[(2-*trans*-methylcyclopropyl)methyl]amino}-6-[methyl(methylsulfonyl) amino]isonicotinate: ¹H NMR (400 MHz, MeOD) δ 7.28 (m, 5H), 7.01 (d, J = 0.8 Hz, 1H), 6.98 (d, J = 0.8 Hz, 1H), 4.83 (s, 2H), 3.87 (s, 3H), 3.62 (dd, J = 6.0, 14.8 Hz, 1H), 3.30 (dd, J = 7.2, 14.8 Hz, 1H), 3.23 (s, 3H), 2.88 (s, 3H), 0.93 (d, J = 6.0 Hz, 3H), 0.81 (m, 1H), 0.62 (m, 1H), 0.39 (m, 1H), 0.22 (m, 1H)

Step C: Hydrogenation


A solution of 2-{benzyl[(2-methylcyclopropyl)methyl]amino}-6-[methyl (methylsulfonyl) amino]isonicotinate (0.93g, 2.23 mmol), 20% palladium hydroxide on carbon (0.042g, 0.06 mmol) and trifluoroacetic acid (0.13g, 1.11 mmol) in ethanol (10 mL) was placed under a hydrogen atmosphere and heated to 60 °C for 3 hours. The reaction was cooled to ambient emperature, filtered over celite, rinsed with methanol and evaporated *in vacuo* to give methyl 2-[[2-(*trans*-methylcyclopropyl)methyl]amino]-6-[methyl(methylsulfonyl)amino]isonicotinate: LCMS [M+H] = 328.1

Step D: Saponification

A solution of methyl 2-[[2-(*trans*-methylcyclopropyl)methyl]amino]-6-[methyl(methylsulfonyl) amino]isonicotinate (0.8g, 2.44 mmol) in methanol (5 mL) and tetrahydrofuran (5 mL) was treated with 1N NaOH (4.9 mL, 4.9 mmol) and the reaction was heated to 50 °C for 1 hour. The


reaction was evaporated *in vacuo* and partitioned between 1M HCl and ethyl acetate. The combined organics were dried over sodium sulfate, filtered and evaporated in vacuo to give 2-
 {[(2-*trans*-methylcyclopropyl)methyl]amino}-6-[methyl(methylsulfonyl)amino] isonicotinic acid
 (A) as a white solid: ^1H NMR (400 MHz, CD_3OD) δ 6.89 (s, 1H), 6.83 (s, 1H), 3.30 (s, 3H),
 5 3.17 (d, $J = 6.8$ Hz, 2H), 3.15 (s, 3H), 1.03 (d, $J = 6.0$ Hz, 3H), 0.81 (m, 1H), 0.64 (m, 1H), 0.39
 (m, 1H), 0.22 (m, 2H); HRMS (ES, $\text{M}+\text{H}$) calcd. for $\text{C}_{13}\text{H}_{19}\text{N}_3\text{O}_4\text{S}$: 314.1169, found: 314.1171.

Intermediate B: 2-[(cyclopropylmethyl)(propyl)amino]-6-
 [methyl(methylsulfonyl)amino]isonicotinic acid (Scheme 4)




Prepared from methyl 2,6-dichloroisonicotinate using a procedure similar to that described for the preparation of Intermediate A: ES MS ($\text{M}+\text{H}$) = 342.

Intermediate C: 2-[methyl(methylsulfonyl)amino]-6-(3-phenylpyrrolidin-1-yl)isonicotinic acid
 (Scheme 4)




Prepared from methyl 2,6-dichloroisonicotinate using a procedure similar to that described for the preparation of Intermediate A: ES MS ($\text{M}+\text{H}$) = 376.

Intermediate D: 2-{[2-(4-fluorophenyl)ethyl]amino}-
 6[methyl(methylsulfonyl)amino]isonicotinic acid (Scheme 4)



Prepared from methyl 2,6-dichloroisonicotinate using a procedure similar to that described for the preparation of Intermediate A: ES MS (M+H) = 368.

5 Intermediate E: 3-((1R)-1-(4-fluorophenyl)ethyl)amino-5-(dimethyl(methylsulfonyl)amino)benzoic acid (Scheme 5)



Step A: Sulfonation

To a stirred slurry of dimethyl 5-aminoisophthalate (5.0 g, 23.90 mmol) in 100 mL CH₂Cl₂ / pyridine (3:1) at 0 °C was added methanesulfonyl chloride (1.85 mL, 23.90 mmol). The resulting mixture was stirred for 4 h at room temperature. The solvent was removed in vacuo and ethylacetate (100 mL) was added resulting in precipitate formation. The product was collected by filtration to give the sulfonamide as a white solid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.15 (s, 1H), 8.02 (s, 2H), 3.89 (s, 6H), 3.02 (s, 3H) LCMS [M-OCH₃]⁺ = 256.16.

15

Step B: Methylation

To a solution of sodium hydride (0.153 g, 3.83 mmol, 60 % oil dispersion) in 10 mL DMF was added sulfonamide (1.0 g, 3.48 mmol) from step A followed by methyl iodide (0.43 mL, 6.97 mmol). After 1 hr the reaction was quenched with H₂O (100 mL) and extracted with EtOAc (3 x 50 mL). The organic extracts were dried over MgSO₄ and evaporated to give the product. ¹H NMR (400 MHz, DMSO-d₆) δ 8.40 (s, 1H), 8.19 (s, 2H), 3.91 (s, 6H), 3.34 (s, 3H), 3.01 (s, 3H). LCMS [M + H]⁺ = 302.15.

20

Step C: Hydrolysis

Diester (1.03 g, 3.38 mmol) from step B was dissolved in 50 mL THF:MeOH (1:1) and cooled to 0°C. 1N NaOH (3.38 mL, 3.38 mmol) was added and the reaction was allowed to warm to RT over 8 hours. The solution was acidified with 1N HCl (30 mL) and extracted with EtOAc (3 x 50 mL). The combined organic extracts were washed with brine and dried over MgSO₄, filtered and concentrated in vacuo. Purification on silica gel (5 % MeOH/CHCl₃ containing 1% HOAc) gave the mono acid. ¹H NMR (400 MHz, DMSO-d₆) δ 8.30 (s, 1H), 8.10 (s, 2H), 3.84 (s, 3H), 3.27 (s, 3H), 2.94 (s, 3H). LCMS (M+H) = 288.16.


Step D: Amine coupling

A solution containing 6.99 g (24.1 mmol) of monoacid from step C in 50 mL DMF, EDC-HCl reagent (6.95 g, 36.2 mmol), (R)-1(4-fluorophenyl)ethylamine (3.37 mL, 24.9 mmol), and 1-hydroxy-7-azabenzotriazole (3.28 g, 24.1 mmol) was stirred at ambient temperature for 1 h. The reaction was diluted with 125 mL EtOAc, washed with aq. 3M LiCl (2x75 mL), followed by 1N HCl (2x75 mL) and dried over Na₂SO₄. Upon solvent removal the product was obtained as a white solid (M+H) = 409.5; ¹H NMR (400 MHz, CDCl₃) δ 8.26 (s, 1H), 8.17 (s, 1H), 8.05 (s, 1H), 7.37 (dd, J = 5.3, 8.6 Hz, 2H), 7.05 (app. t, J = 8.6 Hz, 2H), 6.40 (d, J = 7.1 Hz, 1H), 5.33 (q, J = 7.1 Hz, 1H), 3.96 (s, 3H), 3.37 (s, 3H), 2.88 (s, 3H), 1.64 (d, J = 7.0 Hz, 3H).

Step E: Hydrolysis

To 9.32 g (22.8 mmol) of the benzyl amide from step D in 150 mL THF:MeOH (1:1) was added 3 N NaOH (22.8 mL, 68.4 mmol). The solution was heated to 50 °C for 1 h. After cooling the solution was concentrated to remove MeOH/THF under reduced pressure. The concentrated solution was acidified by the addition of 6 N HCl till pH 2-3 and extracted with EtOAc (2 x 100 mL). The combined organic extracts were washed with brine, dried over Na₂SO₄, filtered, and concentrated in vacuo to give the desired carboxylic acid as a white solid: ¹H NMR (400 MHz, DMSO-d₆) δ 9.11 (d, J = 8.1, 1H), 8.41 (s, 1H), 8.09 (d, J = 9.3 Hz, 2H), 7.44 (m, 2H), 7.16 (t, J = 8.8 Hz, 2H), 5.20 (t, J = 5, 1H), 3.32 (s, 3H), 3.00 (s, 3H), 1.50 (d, J = 7.1 Hz, 3H); LCMS (M+H) = 395.0.

Intermediate F: 5-{[Butyl(methyl)amino]carbonyl}-2'-cyano-1,1'-biphenyl-3-carboxylic acid
(Scheme 5)



Step A and B: Cross-coupling and Saponification.

To a solution of dimethyl 5-iodoisophthalate (13 g, 40.6 mmol) in 100 mL THF was added 2-cyano-phenyl zinc bromide (97.5 mL, 48.7 mmol, 0.5 M THF) and tetrakis(triphenylphosphine) palladium (214 mg, 0.2 mmol) and the reaction mixture was stirred at room temperature for 2 h. The precipitated solid was filtered, the filtrate was diluted with MeOH to provide after filtration a second crop for a total of 10.1 g of dimethyl 5-(2-cyanophenyl)isophthalate which was hydrolyzed to the corresponding monoacid 2'-cyano-5-(methoxycarbonyl)-1,1'-biphenyl-3-carboxylic acid following a similar procedure as described in intermediate B preparation, step C:

¹H NMR (400 MHz, d₆-DMSO) δ 13.55 (br s, 1H), 8.60-8.55 (m, 1H), 8.38-8.31 (m, 2H), 8.02 (d, J = 8.3 Hz, 1H), 7.85 (td, J = 8.3 Hz, 1.5 Hz 1H), 7.75 (d, J = 8.3 Hz, 1H), 7.66 (td, J = 8.3 Hz, 1.5 Hz 1H), 3.93 (s, 3H).

Step C: Amide coupling.


In a 500 mL flask containing 2'-cyano-5-(methoxycarbonyl)-1,1'-biphenyl-3-carboxylic acid (3.0 g, 10.6 mmol) from step B, *N*-methyl-butylamine (1.39g, 16.0 mmol), HOAt (1.45 g, 10.6 mmol) in CH₂Cl₂ was added EDC-HCl (3.06 g, 16.0 mmol) at rt. After stirring overnight the reaction was poured onto 0.1 N HCl, extracted with CH₂Cl₂ (3x75mL) and the combined extracts washed with brine, dried over Na₂SO₄ and concentrated in vacuo. Purification by flash chromatography (30-40% ethyl acetate/hexanes) gave methyl 5-[[butyl(methyl)amino]carbonyl]-2'-cyano-1,1'-biphenyl-3-carboxylate as an oil: amide rotamers present at rt, ¹H NMR (400 MHz, CDCl₃) δ 8.20 (s, 1H), 8.14 (d, J = 4.0 Hz, 1H), 7.76 (m, 2H), 7.66 (t, J = 8.0 Hz, 1H), 7.50 (m, 2H), 3.93 (s, 3H), 3.54 (t, J = 7.6 Hz, 1H), 3.32 (t, J = 7.2 Hz, 1H), 3.08 (s, 1.5 H), 3.00 (s, 1.5H), 1.65 (quint, J = 6.8 Hz, 1H), 1.53 (quint, J = 7.2 Hz, 1H), 1.40 (sext, J = 7.2 Hz, 1H), 1.17 (sext, J = 7.2 Hz, 1H), 0.96 (t, J = 7.2 Hz, 1.5H), 0.79 (t, J = 7.2 Hz, 1.5H).

Step D: Hydrolysis.

Prepared using a procedure similar to Intermediate **B**, step E, Methyl 5-


{[butyl(methyl)amino]carbonyl}-2'-cyano-1,1'-biphenyl-3-carboxylate (3.4 g, 9.7 mmol) from step C above was hydrolyzed to give 5-{[butyl(methyl)amino]carbonyl}-2'-cyano-1,1'-biphenyl-3-carboxylic acid: amide rotamers present at rt, ¹H NMR (400 MHz, CDCl₃) δ 8.26 (s, 1H), 8.21 (d, J = 5.2 Hz, 1H), 7.81 (t, J = 1.6 Hz, 1H), 7.78 (d, J = 8.0 Hz, 1H), 7.67 (t, J = 6.4 Hz, 1H), 7.54-7.47 (m, 2H), 3.57 (t, J = 7.2 Hz, 1H), 3.34 (t, J = 7.2 Hz, 1H), 3.12 (s, 1.5H), 3.04 (s, 1.5H), 1.70 (quint, J = 6.4 Hz, 1H), 1.56 (quint, J = 6.0 Hz, 1H), 1.42 (sext, J = 7.2 Hz, 1H), 1.90 (sext, J = 7.2 Hz, 1H), 0.98 (t, J = 7.2 Hz, 1.5H), 0.80 (t, J = 7.2 Hz, 1.5H); LCMS (M+H) = 337.3

Intermediate G: 2'-cyano-5-({[(1R)-1-(4-fluorophenyl)ethyl]amino}carbonyl)-1,1'-biphenyl-3-carboxylic acid (Scheme 5).



Prepared from methyl dimethyl 5-iodoisophthalate using a procedure similar to that described for the preparation of Intermediate F: ES MS (M+H) = 389.

Intermediate H: 3-[(2-Methylcyclopropyl)methoxy]-5-[methyl(methylsulfonyl)amino]benzoic acid (Scheme 6).



Step A. To a stirred solution of dimethyl 5-hydroxyisophthalate (8.6 g, 41.1 mmol) in 200 mL of acetone was added K₂CO₃ (5.7 g, 41.1 mmol) and trans-crotyl bromide (5.5 g, 41.1 mmol). The resulting mixture was stirred at reflux for 16 h. The solids were removed by filtration and the filtrate was evaporated to near dryness. The resulting residue was dissolved in

200 mL of ether and washed 3 x 20 mL of 1N HCl then brine. The organic extracts were dried over MgSO_4 and evaporated to give aryl ether A. ^1H NMR (CDCl_3) δ 8.25 (s, 1H), 7.75 (s, 2H), 5.93 (m, 1H), 5.77 (m, 1H), 4.58 (d, J = 2.2 Hz, 2H), 3.91 (s, 6H), 1.81 (d, J = 2.2 Hz, 3H). LCMS ($\text{M}+\text{H}$) = 265.24.

5 Step B. A 0°C solution containing 9.4 g (35.6 mmol) of the isophthalate from step A in 300 mL of a 1:1 mixture of THF and MeOH was treated with 35.6 mL (35.6 mmol) of 1N NaOH. The ice bath was allowed to stir to ambient temperature over 16 h. The reaction mixture was concentrated to ca. 1/8 volume before it was acidified with 25 mL of 3N HCl. The solids that precipitated were redissolved in 300 mL of EtOAc and washed with brine (2 x 25 mL). The
10 organic extract was dried over MgSO_4 and evaporated to give the desired carboxylic acid. ^1H NMR (CDCl_3) δ 8.37 (s, 1H), 7.82 (s, 2H), 5.93 (m, 1H), 5.77 (m, 1H), 4.58 (d, J = 2.2 Hz, 2H), 3.95 (s, 3H), 1.77 (d, J = 2.2 Hz, 3H). LCMS ($\text{M}+\text{H}$) = 252.18.

 Step C. To a 0°C solution containing 4.0 g (16.0 mmol) of carboxylic acid from step B above in 80 mL of THF was added 4.2 mL (30.2 mmol) of Et_3N and 2.2 mL (22.7 mmol) of ethyl
15 chloroformate. The resulting slurry was stirred for 1h and treated with 2.46 g (37.8 mmol) of NaN_3 dissolved in 15 mL of water. After an additional hour at rt the reaction mixture was diluted with 50 mL of water and washed with toluene (3 x 50 mL). The combined organic
20 extracts were dried over MgSO_4 and refluxed over 16h. The reaction was cooled to rt and treated with 3.1 mL (30.2 mmol) of benzyl alcohol and 4.2 mL (30.2 mL) of triethylamine. The reaction was refluxed for 24h, cooled and diluted with 100 mL of EtOAc and 35 mL of 10% citric acid. The organic extract was washed with water and brine then dried over MgSO_4 . Column
25 chromatography (2:3 EtOAc/ Hexanes) afforded the carbamate C. ^1H NMR (CDCl_3) δ 7.38 (m, 8H), 6.85 (bs, 1H), 5.85 (m, 1H), 5.65 (m, 1H), 5.20 (s, 2H), 4.44 (d, J =6.0 Hz, 2H), 3.82 (s, 3H), 1.71 (d, 3H). LCMS ($\text{M}+\text{H}$) = 356.25.

 Step D. A solution of 3.56 g (10.0 mmol) of the aryl ether from step C was dissolved in 100 mL of EtOAc and treated with 50 mL (c.a. 0.5 M, 25 mmol) of freshly prepared CH_2N_2 . After stirring for 5 minutes, 112 mg (0.5 mmol) of $\text{Pd}(\text{OAc})_2$ was added to effect vigorous
30 release of N_2 . After an additional 30 minutes, the brown slurry was evaporated and chromatographed (1:1 EtOAc / Hexanes) to give the desired cyclopropylmethyl ether. ^1H NMR (CDCl_3) δ 7.55 (s, 1H), 7.44 (m, 7H), 6.80 (bs, 1H), 5.23 (s, 2H), 3.85 (s, 3H), 3.80 (m, 2H), 1.04 (d, 3H), 0.94 (m, 1H), 0.75 (m, 1H), 0.47 (m, 1H), 0.38 (m, 1H). LCMS ($\text{M}+\text{H}$) = 368.26.

 Step E. To a solution of the benzyl carbamate (3.6 g, 10.0 mmol) from step D and 1.5 g of 10 % Pd/C in EtOAc (100 mL) was stirred at room temperature under a balloon of hydrogen gas for 5 h. The mixture was filtered through a pad of Celite, concentrated, and purified on

silica gel (50 % EtOAc / Hexanes) to afford the desired aniline. ^1H NMR (CDCl_3) δ 6.99 (s, 2H), 6.40 (s, 1H), 3.85 (s, 3H), 3.75 (m, 2H), 1.77 (m, 1H), 1.45 (m, 1H), 1.04 (d, 3H), 0.47 (m, 1H), 0.33 (m, 1H). LCMS (M+H) = 236.2.


Step F. To a 0°C solution of the aniline from step E (940 mg, 4.0 mmol) in 30 mL of CH_2Cl_2 and 5 mL of pyridine was added methanesulfonyl chloride (0.40 mL, 4.0 mmol). The resulting mixture was stirred at this temperature for 2 h before being diluted with 100 mL of DCM. The solution was washed with 1N HCl (3 x 25 mL), water (2 x 25 mL), and brine (25 mL). The organic phase was dried and concentrated to provide sulfonamide F that was used in the next step without further purification. LCMS (M+H) = 314.1.

Step G. The sulfonamide from step F (1.25 g, 4.0 mmol) in DMF (20 mL) was treated with 95 % sodium hydride (106 mg, 4.4 mmol) and excess methyl iodide (3 mL). The resulting mixture was stirred at ambient temperature for 1 h and was diluted with 200 mL of ether. The solution was washed with water (7 x 25 mL) and brine then dried over MgSO_4 . Purification by silica gel chromatography (2:3 EtOAc / Hexanes) afforded the desired methylated sulfonamide. ^1H NMR (CDCl_3 w/0.05% $\text{DMSO}-d_6$) δ 7.65 (s, 1H), 7.41 (s, 1H), 7.15 (s, 1H), 3.93 (s, 3H), 3.80 (t, 2H), 3.30 (s, 3H), 2.87 (s, 3H), 1.11 (d, 3H), 0.88 (m, 1H), 0.55 (m, 1H), 0.37 (m, 1H). LCMS (M+H) = 328.23.

Step H. To a stirred solution of the ester from step G (625 mg, 2.0 mmol) in 12 mL THF/MeOH (1:1) was added 15% NaOH (2.2 mL, 8.0 mmol). After the reaction mixture was stirred at 45°C for 2 h the solvents were evaporated and the residue was acidified with 3N HCl (4.0 mL, 12 mmol). The solid was taken up in 75 mL of DCM and the organic phase was washed with brine. The organic phase was dried and evaporated to yield the desired carboxylic acid 3-[(2-methylcyclopropyl)methoxy]-5-[methyl(methylsulfonyl)amino]benzoic acid as a white solid. ^1H NMR (CDCl_3 w/ 0.05% $\text{DMSO}-d_6$) δ 7.61 (s, 1H), 7.44 (s, 1H), 7.15 (s, 1H), 3.83 (t, 2H), 3.32 (s, 3H), 2.83 (s, 3H), 1.11 (d, 3H), 0.88 (m, 1H), 0.55 (m, 1H), 0.37 (m, 1H). LCMS (M+H) = 314.22.

EXAMPLE 1

N-[(1S,2S)-2-amino-1-benzylhexyl]-2-[[[(2-methylcyclopropyl)methyl]amino]-6-[methyl(methylsulfonyl)amino]isonicotinamide (Scheme 8)



Step A: Amide formation

A solution of acid intermediate **A** (35 mg, 0.112 mmol), amine intermediate **I** (28mg, 0.134 mmol), N,N-diisopropylethylamine (36mg, 0.28 mmol), and HOAT (15mg, 0.112 mmol) in methylene chloride (1.5 mL) was treated with EDC (32mg, 0.168 mmol). After stirring 2 hours at ambient temperature the solution was partitioned between water/methylene chloride. The organics were washed with 1N HCl followed by brine. The combined organics were dried over sodium sulfate, filtered and evaporated *in vacuo* to give N-[(1S,2S)-2-amino-1-benzylhexyl]-2-[[2-(2-methylcyclopropyl)methyl]amino]-6-[methyl(methylsulfonyl)amino]isonicotinamide as a crude oil. LCMS (M + H) = 528.0

Step B: Azide reduction









A solution of crude N-[(1S,2S)-2-amino-1-benzylhexyl]-2-[[2-(2-methylcyclopropyl)methyl]amino]-6-[methyl(methylsulfonyl)amino]isonicotinamide in methanol (2 mL) and 10% palladium on carbon (12 mg) in degassed methanol was placed under a hydrogen atmosphere for 1 hour. The reaction was filtered through celite, rinsed with methanol and evaporated *in vacuo*. Purification by reverse phase LC gave N-[(1S,2S)-2-amino-1-benzylhexyl]-2-[[2-(2-methylcyclopropyl)methyl]amino]-6-[methyl(methylsulfonyl)amino]isonicotinamide. ¹H NMR (CD₃OD) δ 7.28 (m, 5H), 6.55 (s, 1H), 6.44 (s, 1H), 4.35 (m, 1H), 3.42 (m, 1H), 3.29 (s, 3H), 3.16 (m, 5H), 3.00 (m, 2H), 1.85 (m, 1H), 1.72 (m, 1H), 1.43 (m, 4H), 1.05 (d, J = 5.96Hz, 3H), 0.98 (t, J = 7.14Hz, 3H), 0.80 (m, 1H), 0.65 (m, 1H), 0.41 (m, 1H), 0.24 (m, 1H) LCMS [M + H]⁺ = 314.1.

The following examples were prepared in an analogous manner to that described in Example 1 using various combinations of Intermediates **I** – **XIV** or related derivatives thereof and Intermediate acids of types **A** – **H** or related derivatives thereof.








Example	Structure	Schemes	Intermediates	ES MS M+H
2		4, 8		439
3		4, 8		433
4		4, 8		475
5		2, 4, 8		481
6		4, 8		451
7		4, 8		488
8		4, 8		467
9		4, 8		506

Example	Structure	Schemes	Intermediates	ES MS M+H
10		4, 8		504
11		4, 8		518
12		4, 8		520
13		4, 8		520
14		4, 8		492
15		4, 8		506
16		2, 4, 8		503
17		4, 8		534









Example	Structure	Schemes	Intermediates	ES MS M+H
18		2, 4, 8		475
19		4, 8	C	515
20		4, 8	C	509
21		2, 4, 8		511
22		4, 8	D	507
23		2, 4, 8		517
24		2, 4, 8		503
25		4, 8		507








Example	Structure	Schemes	Intermediates	ES MS M+H
26		4, 8		530
27		4, 8		523
28		4, 8		491
29		4, 8		529
30		4, 8		507
31		4, 8		519
32		4, 8		523
33		4, 8		502

Example	Structure	Schemes	Intermediates	ES MS M+H
34		3, 4, 8	A	446
35		1, 3, 4, 8	A, I	502
36		3, 4, 8	A	483
37		1, 3, 4, 8	A, IX	539
38		1, 3, 4, 8	A, VIII	538
39		1, 3, 4, 8	A, VII	509
40		1, 3, 4, 8	A, VI	466

Example	Structure	Schemes	Intermediates	ES MS M+H
41		1, 3, 4, 8	A, V	508
42		1, 5, 8	F, I	525
43		1, 5, 8	F, II	525
44		1, 5, 8	F, III	526
45		1, 5, 8	F, IV	526
46		1, 5, 8	I	619
47		1, 5, 8	I	575

Example	Structure	Schemes	Intermediates	ES MS M+H
48		1, 5, 8	E, III	584
49		1, 5, 8	E, V	589
50		1, 5, 8	I	648
51		6, 8		433
52		5, 8		484
53		5, 8		445
54		5		496
55		5		496

Example	Structure	Schemes	Intermediates	ES MS M+H
56		5, 8	F	476
57		5, 8	F	506
58		5		513
59		5, 8	G	522
60		5, 8	G	528
61		5, 8		565
62		5, 8		571
63		5, 8		565

Example	Structure	Schemes	Intermediates	ES MS M+H
64		5, 8		555
65				435
66		1,8	A, XII	518
67		1,8	XII	608
68		1,8	XIII	488
69		1,8	XIII	516
70		1,8	XIII	488


Example	Structure	Schemes	Intermediates	ES MS M+H
71		1,8	XIII	502
72		1,8	XIII	502
73		1,8	XIV	506
74		1,8	XIV	534
75		1,8	XIV	506
76		7,8	XIV	502
77		5,8		554

While the invention has been described and illustrated with reference to certain particular embodiments thereof, those skilled in the art will appreciate that various adaptations, changes, modifications, substitutions, deletions, or additions of procedures and protocols may be made

without departing from the spirit and scope of the invention. It is intended, therefore, that the invention be defined by the scope of the claims that follow and that such claims be interpreted as broadly as is reasonable.

WHAT IS CLAIMED IS:

1. A compound of formula (I):



5 wherein

Y^1 is CH or N;

Q is selected from the group consisting of

- 10 (1) $-OH$, and
(2) $-NH_2$;

R^a is selected from the group consisting of

- 15 (1) hydrogen,
(2) $-C_{1-10}$ alkyl, wherein said alkyl is unsubstituted or substituted with one or more fluoro, and
(3) $-C_{3-8}$ cycloalkyl;

R^b is selected from the group consisting of

- 20 (1) hydrogen,
(2) $-C_{1-10}$ alkyl, wherein said alkyl is unsubstituted or substituted with one or more fluoro,
(3) $-C_{3-8}$ cycloalkyl,
(4) $-(CH_2)_n-NR^cR^d$ wherein R^c and R^d are selected from the group consisting of
25 hydrogen and C_{1-10} alkyl, and n is 2, 3 or 4, and
(5) $-(CH_2)_{n'}-O-R^e$ wherein R^e is C_{1-10} alkyl, and n' is 1, 2, 3 or 4;

m is 1 or 2;

R¹ is (1) aryl selected from the group consisting of phenyl and naphthyl, or
 (2) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl,
 pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl,
 pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl,
 5 oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,
 (3) -C₁₋₁₀ alkyl, and
 (4) -C₃₋₈ cycloalkyl,
 wherein said aryl, heteroaryl, alkyl and cycloalkyl is unsubstituted or substituted with
 one or more

- 10 (a) halo,
 (b) -OH,
 (c) -CN,
 (d) -O-C₁₋₁₀ alkyl,
 (e) -C₁₋₁₀ alkyl,
 15 (f) -C₃₋₈ cycloalkyl,
 (g) aryl selected from the group consisting of phenyl and naphthyl, or
 (h) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl,
 pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl,
 triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl,
 20 isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl,
 benzimidazolyl and benzoxazolyl;

R² is selected from the group consisting of:

- (1) (R⁴-SO₂)N(R⁷)-, wherein R⁴ is
 25 (a) -C₁₋₁₀ alkyl,
 (b) -C₃₋₈ cycloalkyl,
 wherein said alkyl and cycloalkyl is unsubstituted or substituted with one or more
 (i) halo,
 (ii) -OH,
 30 (iii) -CN,
 (iv) -O-C₁₋₁₀ alkyl,
 (v) -C₁₋₁₀ alkyl,
 (vi) -C₃₋₈ cycloalkyl,
 (vii) aryl selected from the group consisting of phenyl and naphthyl, or

(viii) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl;

and said aryl and heteroaryl is unsubstituted or substituted with one or more


- (A) halo,
- (B) -OH,
- (C) -CN,
- (D) -O-C₁₋₁₀ alkyl,
- (E) -C₃₋₈ cycloalkyl, or
- (F) -C₁₋₁₀ alkyl,

(c) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,

wherein said heteroaryl is unsubstituted or substituted with one or more

- (i) halo,
- (ii) -OH,
- (iii) -CN,
- (iv) -O-C₁₋₁₀ alkyl,
- (v) -C₃₋₈ cycloalkyl, or
- (vi) -C₁₋₁₀ alkyl,

(d) -(CH₂)_x-NR^fR^g wherein R^f and R^g are selected from the group consisting of hydrogen and C₁₋₁₀ alkyl, and x is 1, 2, 3 or 4, or R^f and R^g, together with the nitrogen atom to which they are attached from the group



wherein y is 1 or 2, Y^5 is $-\text{CHR}^{21}$, $-\text{O}-$ or NR^{21} , wherein R^{21} is selected from the group consisting of;

- (i) hydrogen, and
- (ii) C_{1-10} alkyl,

wherein said alkyl is unsubstituted or substituted with one or more

- A) halo,
- B) $-\text{OH}$,
- C) $-\text{CN}$,
- D) $-\text{O}-\text{C}_{1-10}$ alkyl, or
- E) $-\text{C}_{3-8}$ cycloalkyl;

R^7 is selected from the group consisting of

- (a) hydrogen, and
- (b) $-\text{C}_{1-10}$ alkyl,

wherein said alkyl is unsubstituted or substituted with one or more


- (i) halo,
- (ii) $-\text{OH}$,
- (iii) $-\text{CN}$,
- (iv) $-\text{O}-\text{C}_{1-10}$ alkyl,
- (v) $-\text{C}_{3-8}$ cycloalkyl,
- (vi) aryl selected from the group consisting of phenyl and naphthyl, or
- (vii) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,

wherein said cycloalkyl, aryl or heteroaryl is unsubstituted or substituted with one or more

- (A) halo,

- (B) $-\text{OH}$,
 (C) $-\text{CN}$,
 (D) $-\text{O}-\text{C}_{1-10}$ alkyl,
 (E) $-\text{C}_{3-8}$ cycloalkyl, or
 (F) aryl selected from the group consisting of phenyl and naphthyl;

(c) $-(\text{CH}_2)_{y'}-\text{NR}^{\text{h}}\text{R}^{\text{i}}$ wherein R^{h} and R^{i} are selected from the group consisting of hydrogen and C_{1-10} alkyl, and y' is 1, 2, 3 or 4, or R^{h} and R^{i} , together with the nitrogen atom to which they are attached from the group




wherein y' is 1 or 2, Y^6 is $-\text{CHR}^{22}$, $-\text{O}-$ or NR^{22} , wherein R^{22} is selected from the group consisting of;

- (i) hydrogen, and
 (ii) C_{1-10} alkyl,

wherein said alkyl is unsubstituted or substituted with one or more


- A) halo,
 B) $-\text{OH}$,
 C) $-\text{CN}$,
 D) $-\text{O}-\text{C}_{1-10}$ alkyl, or
 E) $-\text{C}_{3-8}$ cycloalkyl,

or R^4 and R^7 are linked together to form the group



wherein z is 1, 2 or 3;


(2)



wherein R^8 is selected from the group consisting of


- (a) $-\text{CN}$,
 (b) hydrogen, and
 (c) tetrazolyl;

(3)





wherein o is 1, 2, 3 or 4; and

(4)



wherein Y^2 is $-\text{NH}=\text{CH}-$ or $-\text{CH}=\text{NH}-$;

15 R^3 is selected from the group consisting of



wherein Y^3 is CR^{6c} or N;

R^5 is C_{1-10} alkyl or C_{1-2} perfluoroalkyl;

5 R^{6a} , R^{6b} , and R^{6c} are independently selected from the group consisting of:

- (1) hydrogen,
- (2) halo,
- (3) $-C_{1-10}$ alkyl,
- (4) $-OH$,
- 10 (5) $-CN$,
- (6) $-C_{3-8}$ cycloalkyl, and
- (7) $-O-C_{1-10}$ alkyl;


R^9 and R^{10} are independently selected from the group consisting of

- 15 (1) hydrogen,
- (2) $-C_{1-10}$ alkyl, and
- (3) $-C_{3-8}$ cycloalkyl,

wherein said alkyl and cycloalkyl is unsubstituted or substituted with one or more

- (a) halo,
- 20 (b) $-OH$,
- (c) $-CN$,
- (d) $-O-C_{1-10}$ alkyl,
- (e) $-C_{3-8}$ cycloalkyl, and
- (f) $-NR^j R^k$ wherein R^j and R^k are C_{1-10} alkyl;

25 or R^9 and R^{10} are joined together with the nitrogen atom to which they are attached to form



30 wherein w is 1, 2 or 3, and

R^{23} is selected from the group consisting of

- (a) hydrogen,
 (b) -C₁₋₁₀ alkyl,
 (c) -C₃₋₈ cycloalkyl,
 (d) -C₂₋₁₀ alkenyl,
 (e) -C₂₋₁₀ alkynyl,
 (f) -(CH₂)_p-phenyl,
 (g) -(CH₂)_p-heteroaryl, wherein said heteroaryl is selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinoliny, isoquinoliny, benzimidazolyl and benzoxazolyl,

wherein p is 0 or 1, and

wherein said alkyl, alkenyl, alkynyl, cycloalkyl, phenyl and heteroaryl is unsubstituted or substituted with one or more

- i) halo,
 ii) -C₁₋₁₀ alkyl,
 iii) -OH,
 iv) -CN,
 v) -C₃₋₈ cycloalkyl, or
 vi) -O-C₁₋₁₀ alkyl;


R¹¹ is selected from the group consisting of

- (1) -CH-
 (2) -CH₂-,
 (3) -O-, and
 (4) -NR¹⁷-,

provided that when R¹¹ is -CH- the dotted line forms a bond and when R¹¹ is -CH₂-, -O- or -NR¹⁷- the dotted line is absent;

R¹⁷ is hydrogen or C₁₋₁₀ alkyl, wherein said C₁₋₁₀ alkyl is unsubstituted or substituted with one or more

- (a) halo,
 (b) -OH,
 (c) -CN,
 (d) -C₃₋₈ cycloalkyl,
 (e) -O-C₁₋₁₀ alkyl,
 (f) -(CH₂)_q-phenyl, wherein q is 1 or 2, and
 (g) -(CH₂)_{q'}-NR¹⁸R¹⁹, wherein q' is 2, 3 or 4, and
 wherein R¹⁸ and R¹⁹ are independently selected from the group
 consisting of
 i) hydrogen, or
 ii) C₁₋₁₀ alkyl;
 or R¹⁸ and R¹⁹, together with the nitrogen atom to which they are
 attached, form the group



- wherein q'' is 1 or 2, Y⁷ is -CHR²⁴, -O- or NR²⁴, wherein R²⁴ is
 selected from the group consisting of;
 (c) hydrogen, and
 (d) C₁₋₁₀ alkyl,
 wherein said alkyl is unsubstituted or substituted with one or more
 i) halo,
 ii) -OH,
 iii) -CN,
 iv) -O-C₁₋₁₀ alkyl, or
 v) -C₃₋₈ cycloalkyl;

R¹² is selected from the group consisting of

- (1) hydrogen,
 (2) -C₁₋₁₀ alkyl, wherein said alkyl is unsubstituted or substituted with one or more
 (a) halo,
 (b) -OH,

- (c) -CN,
- (d) -C₃₋₈ cycloalkyl,
- (e) -O-C₁₋₁₀ alkyl, or
- (f) -NH₂,

- 5 (3) halo,
- (4) -C₃₋₈ cycloalkyl,
- (5) aryl selected from the group consisting of phenyl and naphthyl, and
- (6) heteroaryl selected from the group consisting of pyrazinyl, pyrazolyl,
- pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl,
- 10 triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl,
- isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl,
- benzimidazolyl and benzoxazolyl,

wherein said aryl and heteroaryl is unsubstituted or substituted with one or more

- 15 (a) halo,
- (b) -OH,
- (c) -CN,
- (d) -O-C₁₋₁₀ alkyl,
- (e) -C₃₋₈ cycloalkyl, or
- 20 (f) -C₁₋₁₀ alkyl;

R¹³ is selected from the group consisting of

- (1) hydrogen,
- (2) C₁₋₁₀ alkyl, and
- 25 (3) -C₃₋₈ cycloalkyl;

wherein said alkyl and cycloalkyl is unsubstituted or substituted with one or more

- (a) halo,
- (b) -OH,
- (c) -CN,
- 30 (d) -C₃₋₈ cycloalkyl,
- (e) -O-C₁₋₁₀ alkyl, and
- (f) -C₁₋₁₀ alkyl;

R¹⁴ is selected from the group consisting of

(1) -C₁₋₁₀ alkyl, and

(2) -C₃₋₈ cycloalkyl;

wherein said alkyl and cycloalkyl is unsubstituted or substituted with one or more

(a) halo,

(b) -OH,

(c) -CN,

(d) -C₃₋₈ cycloalkyl,

(e) -O-C₁₋₁₀ alkyl, or

(f) -C₁₋₁₀ alkyl;

(3) -(CH₂)_v-NR¹⁵R¹⁶, wherein v is 2, 3 or 4, and

wherein R¹⁵ and R¹⁶ are independently selected from the group consisting of

a) hydrogen, or

b) C₁₋₁₀ alkyl, wherein said C₁₋₁₀ alkyl is

unsubstituted or substituted with one or more

i) halo,


ii) -OH,

iii) -CN,

iv) -C₃₋₈ cycloalkyl, or

v) -O-C₁₋₁₀ alkyl;

or R¹⁵ and R¹⁶, together with the nitrogen atom to which they are attached, form the group



wherein s is 1 or 2, Y⁴ is -CHR²⁴-, -O- or -NR²⁴-, wherein R²⁴ is selected from the group consisting of

i) hydrogen, and

ii) C₁₋₁₀ alkyl,

wherein said alkyl is unsubstituted or substituted with one or more

A) halo,

B) -OH,


- C) -CN,
 D) -O-C₁₋₁₀ alkyl, or
 E) -C₃₋₈ cycloalkyl,

4) -(CH₂)_r-phenyl, wherein r is 1, 2, 3, or 4, and

wherein said phenyl is unsubstituted or substituted with one or more

- (a) halo,
 (b) -OH,
 (c) -CN,
 (d) -O-C₁₋₁₀ alkyl,
 (e) -C₃₋₈ cycloalkyl, or
 (f) -C₁₋₁₀ alkyl;

or R¹³ and R¹⁴, together with the nitrogen atom to which they are attached, form the group



wherein u is 1 or 2, Y⁸ is -CHR²⁵-, -O- or -NR²⁵-, wherein R²⁵ is selected from the group consisting of

- a) hydrogen,
 b) C₁₋₁₀ alkyl,
 c) -(CH₂)_t-phenyl,
 d) -(CH₂)_t-heteroaryl, wherein said heteroaryl is selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,


wherein t is 0 or 1, and

wherein said alkyl, phenyl and heteroaryl is unsubstituted or substituted with one or more

- i) halo,
- ii) $-C_{1-10}$ alkyl,
- iii) $-OH$,
- iv) $-CN$,
- v) $-C_{3-8}$ cycloalkyl, or
- vi) $-O-C_{1-10}$ alkyl;


and pharmaceutically acceptable salts thereof.

2. The compound of Claim 1 wherein R^a and R^b are both hydrogen.
3. The compound of Claim 1 wherein R^a is hydrogen and R^b is C_{1-10} alkyl.
4. The compound of Claim 1 wherein m is 1 and R^1 is selected from the group consisting of
 - (1) phenyl, unsubstituted or substituted in one or two positions with halo; and
 - (2) thienyl.
5. The compound of Claim 1 wherein R^2 is $(R^4-SO_2)N(R^7)-$.
6. The compound of Claim 5 wherein R^4 and R^7 are each C_{1-6} alkyl.
7. The compound of Claim 1 wherein R^3 is (1)




wherein Y^3 is CHR^{6c} , R^5 is methyl, R^{6a} and R^{6c} are hydrogen and R^{6b} is fluoro.

8. The compound of Claim 1 wherein R^3 is (1)




Y^3 is N, R^5 is C_{1-2} perfluoroalkyl, and R^{6a} and R^{6b} are hydrogen.

9. The compound of Claim 1 wherein R^3 is (2)



and R^9 and R^{10} are each unsubstituted C_{1-10} alkyl, or R^9 and R^{10} are joined together with the nitrogen atom to which they are attached to form attached to form




wherein w is 1;

R^{23} is $-(CH_2)_p$ -phenyl or $-(CH_2)_p$ -heteroaryl, wherein said heteroaryl is selected from the group consisting of pyrazinyl, pyrazolyl, pyridazinyl, pyridyl, pyrimidinyl, pyrrolyl, tetrazolyl, furanyl, imidazolyl, triazinyl, pyranyl, thiazolyl, thienyl, thiophenyl, triazolyl, oxazolyl, isoxazolyl, thiazolyl, oxadiazolyl, indolyl, quinolinyl, isoquinolinyl, benzimidazolyl and benzoxazolyl,


wherein the phenyl and heteroaryl are unsubstituted or substituted with one or more chloro, and p is 0.

10. The compound of Claim 1 wherein R^3 is (3)




R¹¹ is NR¹⁷ wherein R¹⁷ is hydrogen or C₁₋₃ alkyl, and R¹² is hydrogen or methyl.

11. The compound of Claim 1 wherein R³ is (4)




5 R¹³ is hydrogen and R¹⁴ is -(CH₂)_v-NR¹⁵R¹⁶ wherein v is 2 and R¹⁵ and R¹⁶ are each C₁₋₁₀ alkyl, which is unsubstituted or substituted with -OH, -CN or -OCH₃.

12. The compound of Claim 1 wherein R³ is (4)




10 wherein R¹³ and R¹⁴, together with the nitrogen atom to which they are attached, form the group




15 wherein u is 1 or 2, Y⁸ is -CHR²⁵-, -O- or -NR²⁵-.

13. The compound of Claim 1 which is a compound of formula (II)




20 wherein Q, R^a, R^b, R¹, R², R¹², R¹⁷ and m are as defined in Claim 1, and pharmaceutically acceptable salts thereof.

14. The compound of Claim 1 which is a compound of formula (III)




wherein Q, R^a, R^b, R¹, R², R¹³, R¹⁴ and m are defined as in Claim 1, and pharmaceutically
5 acceptable salts thereof.






15. The compound of Claim 1 which is a compound of formula (IV):













wherein Q, R^a, R^b, R¹, R² and m are as defined in Claim 1, and R³ is (1) or (2) as defined in
10 Claim 1, and pharmaceutically acceptable salts thereof.






16. A compound which is selected from the group consisting of












































c














































5



and pharmaceutically acceptable salts thereof.

10

17. A pharmaceutical composition comprising a therapeutically effective amount of a compound of Claim 1 and a pharmaceutically acceptable carrier.

5 18. A method for inhibition of β -secretase activity in a mammal in need thereof which comprises administering to the mammal a therapeutically effective amount of a compound of Claim 1.

10 19. A method for treating Alzheimer's disease in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of Claim 1.

20. A method for ameliorating or controlling Alzheimer's disease in a patient in need thereof comprising administering to the patient a therapeutically effective amount of a compound of Claim 1.



ABSTRACT OF THE INVENTION

The present invention is directed to phenylamide and pyridylamide derivative compounds which are inhibitors of the beta-secretase enzyme and that are useful in the treatment of diseases in which the beta-secretase enzyme is involved, such as Alzheimer's disease. The invention is
5 also directed to pharmaceutical compositions comprising these compounds and the use of these compounds and compositions in the treatment of such diseases in which the beta-secretase enzyme is involved.